East Tennessee State University

Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations

Student Works

12-2014

HIF-1α in the Heart: Provision of Ischemic
Cardioprotection and Remodeling of Nucleotide
Metabolism
Joe Wu
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Systems and Integrative Physiology Commons
Recommended Citation
Wu, Joe, "HIF-1α in the Heart: Provision of Ischemic Cardioprotection and Remodeling of Nucleotide Metabolism" (2014). Electronic
Theses and Dissertations. Paper 2450. https://dc.etsu.edu/etd/2450

This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State
University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East
Tennessee State University. For more information, please contact digilib@etsu.edu.

HIF-1α in the Heart: Provision of Ischemic Cardioprotection and Remodeling of
Nucleotide Metabolism

A dissertation
presented to
the faculty of the Department of Biomedical Sciences
East Tennessee State University

In partial fulfillment
of the requirements for the degree
Doctor of Philosophy in Biomedical Science

by
Joe Wu
December 2014

Gary Wright, Ph.D., Chair
Stacy Brown, Ph.D.
Donald Hoover, Ph.D.
Richard Kostrzewa, Ph.D.
Krishna Singh, Ph.D.
William Stone, Ph.D.
Keywords: HIF-1α, ischemia, cardioprotection, purine nucleotide cycle, HPRT
nucleotide salvage, nucleotide metabolism, adenosine deaminase, adenosine toxicity

ABSTRACT
HIF-1α in the Heart: Provision of Ischemic Cardioprotection and Remodeling of
Nucleotide Metabolism
by
Joe Wu

In our studies we found that stabilized expression of HIF-1α in heart led to better
recovery of function and less tissue death after 30 minutes of global ischemia, via
mechanisms that preserve the mitochondrial polarization. Our group previously showed
that HIF-1α conferred ischemic tolerance by allowing cardiomyocytes to use fumarate
as an alternative terminal electron acceptor to sustain anaerobic mitochondrial
polarization. The source of fumarate was identified as the purine nucleotide cycle
(PNC). Here we discovered that HIF-1α upregulates AMP deaminase 2 (AMPD2), the
entry point to the PNC. The combination of glycolysis and the PNC may protect the
heart's nucleotide resources. We subsequently examined the effects that HIF-1α exerts
on nucleotide metabolism in the ischemic heart. We found that HIF-1α expression
reduces adenosine accumulation in the ischemic heart. As ATP is depleted during
ischemia, AMP accumulates. Our results suggest that AMP metabolism is shunted
towards AMPD2 rather than the adenosine producing 5'-nucleotidase pathway.
Subsequently, we treated hearts with the PNC inhibitor hadacidin followed by 30
minutes of global ischemia. Inclusion of hadacidin reduced ATP and adenylate energy
charge in the hearts. These findings allow us to propose that activity of the PNC
prevents the F0F1 ATP synthase from consuming glycolytic ATP in order to maintain
mitochondrial polarization during ischemia. Thus, the PNC provides ATP sparing
2

effects and preserves the energy charge in the ischemic heart. The fact that ATP and
adenylate energy charge is better preserved during the initial 20 minutes of ischemia in
HIF-1α expressing hearts is supportive of our observation that HIF-1α upregulates the
PNC. HIF-1α also upregulates adenosine deaminase, which degrades adenosine. The
limitation of adenosine accumulation may help HIF-1α expressing hearts avoid toxicity
due to chronic adenosine exposure. Finally, we found that HIF-1α induces the
expression of the nucleotide salvage enzyme hypoxanthine phosphoribosyl transferase
(HPRT). Upon reperfusion HPRT serves to reincorporate the nucleotide degradation
product, hypoxanthine, into the adenylate pool and may prevent the production of
reactive oxygen species. Collectively, HIF-1α robustly protects the heart from ischemic
stress and it upregulates several pathways whose cardioprotective role may extend
beyond the remodeling of nucleotide metabolism.
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CHAPTER 1
INTRODUCTION

Diatomic oxygen (O2) has not always been a major component of the earth's
atmosphere. For instance, during the early Proterozoic era O2 content was less than
10-5 times that found in the present day atmosphere (Pavlov and Kasting 2002). During
that time photosynthetic organisms released O2 into the atmosphere as a metabolic
waste product. However, the O2 released readily reacted with iron and other organic
matter (i.e. O2 sinks). Approximately 2.4 billion years ago the O2 sinks became
saturated and atmospheric O2 levels began to accumulate to that found in the present
day atmosphere. Concurrently, O2 consuming organisms started to evolve.
In regards to the importance of oxygen in sustaining life of aerobic organisms,
Semenza has said that "no substance which when withheld causes death faster"
(Semenza 1998). This is because O2 is crucial to cellular survival as it is coupled to
oxidative phosphorylation in order to produce the cell's energy currency, ATP (Figure
1.1). Mechanistically, electron pairs can enter the electron transport chain at complex I
(I, NADH-CoQ reductase) or complex II (II, succinate-CoQ reductase). Electrons
proceed to complex III (III, CoQ-cytochrome C reductase) then to complex IV (IV,
cytochrome C oxidase) (Figure 1.1). At complexes I, III, and IV, H+ ions are
translocated into the intermembrane space as electrons proceed down the redox
gradient. A total of 10 or 6 H+ are translocated depending on whether NADH or
succinate is used as the initial electron donor. 4H+ re-enter the mitochondrial matrix to
power the F0F1 ATP synthase so that production of ATP can occur. Compared to
11

glycolysis alone, which only generates a net of 2 ATP molecules per glucose, aerobic
respiration can generate 30 ATP molecules per glucose and is therefore much more
efficient (Rich 2003). Given the importance of O2 for survival, an intricate method of
oxygen sensing and ability to adapt in oxygen poor environments exists. This is evident
by the ability of humans to survive altitudes as high as 29,000 feet as in the case of
Messner and Habeler in their ascend of Mount Everest without oxygen
supplementation.

Figure 1.1: O2 is coupled to the synthesis of ATP via oxidative phosphorylation. Electrons can
enter the electron transport chain at I (NADH-CoQ reductase) or at II (succinate-CoQ
reductase). In either case, 2e- are passed onto III (CoQ-cytochrome C reductase) then onto IV
(cytochrome C oxidase). The passing of an electron pair down the electron transport chain
leads to 10 H+ and 6 H+ that are translocated to the intermembrane space depending on
whether NADH or succinate is used as the initial donor, respectively. The translocation of H+
into the intermembrane space sets up an electrochemical gradient, which is then used to power
ATP synthesis. Adapted from Lodish et al. (2007).

The cell's adaptive responses to inadequate oxygen supply is mediated by a
transcription factor known as hypoxia inducible factor-1 (HIF-1). HIF-1 was identified
and named by Semenza and Wang in their effort to find the transcription factor binding
to a 50 nucleotide hypoxia inducible enhancer on the human erythropoietin gene
(Semenza and Wang 1992). Later work revealed that HIF-1 is composed of a 120 kDa
12

α subunit (HIF-1α) and a 91-94 kDa β subunit (HIF-1β) (Wang and Semenza 1995).
Structurally, HIF-1 belongs to the basic helix-loop-helix PAS family of transcription
factors (Wang et al. 1995).

While HIF-1β is constitutively expressed in the nucleus (Jiang et al. 1996), the
cellular level of HIF-1α is tightly regulated by O2. Under normoxic conditions a family of
prolyl hydroxylase domain containing enzymes (PHDs) hydroxylate proline residues
(Bruick and McKnight 2001; Epstein et al. 2001) on HIF-1α's oxygen-dependent
degradation (ODD) domain. It has been recognized that these residues are proline 402
and proline 564 (Ivan et al. 2001; Jaakkola et al. 2001; Yu et al. 2001; Chan et al.
2005). Hydroxylation of these proline residues subsequently allows for interaction of
von Hippel-Lindau (VHL) tumor suppressor with HIF-1α. Once VHL binds, HIF-1α
becomes polyubiquintinated and is subsequently directed towards proteasomal
degradation (Figure 1.2). The transcriptional activity of HIF-1α is also controlled by
oxygen. During normoxia factor inhibiting HIF (FIH) hydroxylates asparagine residue
803 (Mahon et al. 2001; Hewitson et al. 2002; Lando, Peet, Gorman, et al. 2002).
Hydroxylation of this asparagine residue prevents the binding of transcriptional
coactivators CBP/p300 to HIF-1α's c-terminal transactivation domain (Lando, Peet,
Whelan, et al. 2002). Upon stabilization HIF-1α translocates into the nucleus and
dimerizes with the β subunit (Jiang et al. 1996; Chilov et al. 1999) where transcription of
genes containing the core 5'-RCGTG-3' hypoxic response element occurs (Semenza et
al. 1996) (Figure 1.3).
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Hypoxia inducible factor-1 has been shown to elicit the upregulation of a vast
array of genes. An important adaptation mediated by HIF-1 is ATP production in the
absence of oxidative phosphorylation via glycolysis. As such, the core hypoxic
response element has been found in genes encoding various enzymes of the glycolytic
pathway (Semenza et al. 1996). HIF-1 also stimulates the expression of glucose
transporters in order to increase cellular glucose uptake (Hayashi et al. 2004; Baumann
et al. 2007). Hypoxia inducible factor overexpression is a common theme observed in
cancer and is associated with VHL deficiency in renal cell carcinoma (Maxwell et al.
1999; Zhong et al. 1999). Therefore, it was not surprising that German physiologist Otto
Warburg observed that cancer cells readily produce ATP through glycolysis rather than
oxidative phosphorylation even in the presence of oxygen. This phenomenon was
rightfully named the "Warburg effect" (Warburg 1956). Semenza has recently found
that HIF-1α drives the Warburg effect in cancer (Semenza 2007). Besides the induction
of glycolysis HIF-1 also upregulates genes that promote oxygen delivery to the cell. As
mentioned previously, HIF-1 is responsible for inducing the expression of erythropoietin,
which stimulates red blood cell synthesis and an increase in hematocrit (Semenza and
Wang 1992). Furthermore, HIF-1 increases the expression of vascular endothelial
growth factor (VEGF) to promote angiogenesis (Liu et al. 1995; Carmeliet et al. 1998;
Ryan et al. 1998).
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Figure 1.2: HIF-1α protein level and activity is tightly regulated by oxygen. Hydroxylation of
proline (Pro) residues 402 and 564 by prolyl hydroxylase (PHD) allows von Hippel-Lindau (VHL)
factor to recognize and bind to HIF-1α's oxygen dependent degradation domain (ODD).
Subsequently HIF-1α is ubiquitinated and directed towards proteasomal degradation. Under
normoxic conditions HIF-1α transcriptional activity is also suppressed. Factor inhibiting HIF
(FIH) hydroxylates asparagine (Asn) residue 803, thus preventing the binding of transcriptional
co-activators CBP/p300 at HIF-1α's c-terminal transactivation domain (cTAD). Adapted and
modified from Semenza (2004).

Figure 1.3: Decline in O2 during hypoxia suppresses the activity of PHDs and FIH, thus
stabilizing and activating HIF-1α. O2 is a cofactor that is needed for the enzymatic activity of
15

PHDs and FIH. When O2 level declines, PHDs and FIH activity is abrogated thus stabilizing and
activating HIF-1α. HIF-1α translocates into the nucleus, dimerizes with HIF-1β to initiate the
transcription of genes containing the core 5'-RCGTG-3' hypoxia response element (HRE).
Adapted and modified from Semenza (2004).

O2 delivery to the heart tissue is diminished during ischemia. It is now
recognized that HIF-1α may play a central role in cardioprotection during ischemic
stress. Ischemic preconditioning is a phenomenon whereby exposure of hearts to short
sublethal durations of ischemia-reperfusion is able to provide protection from further
damage upon exposure to subsequent longer and lethal episodes of ischemic stress.
Following a preconditioning protocol consisting of 4 rounds of 5 minutes of ischemia/5
minutes of reperfusion an increase in HIF-1α protein levels was observed (Eckle et al.
2008). In mouse models with a null allele of the HIF-1α locus a loss of preconditioning
protection in heart was noted (Cai et al. 2003; Cai et al. 2008). Also, repression of HIF1α via siRNA was found to attenuate ischemic preconditioning protection (Eckle et al.
2008). Ockaili et al. and Poynter et al. demonstrated that the use of pharmacologic
inhibitors of prolyl hydroxylase to induce HIF-1α also confers cardioprotection (Ockaili et
al. 2005; Poynter et al.). Similarly, administration of siRNA which silences prolyl
hydroxylase or knockout of prolyl hydroxylases to stabilize HIF-1α have proven to be
cardioprotective (Natarajan et al. 2006; Hyvarinen et al.). A drawback to studies using
PHD inhibitors or knockout is that prolyl hydroxylases mediates pathways in addition to
HIF-1α (Cummins et al. 2006; Elvidge et al. 2006). As a result ischemic
cardioprotection provided by PHD inhibition cannot be solely attributed to HIF-1α
expression. Nevertheless, recent findings strongly indicate a prominent role for HIF-1α
in cardioprotection during ischemia.
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As previously mentioned, HIF-1α is degraded in the presence of oxygen. In
order to assess the direct effects that HIF-1α expression exerts on the heart, we used a
mouse model containing a cardiac-specific and doxycycline regulated HIF-1α transgene
that is mutated to be stable and active in the presence of oxygen, thus circumventing
the oxygen mediated degradation and suppression of HIF-1α. Using this mouse model
we sought to: 1) establish the cardioprotective role of HIF-1α; 2) identify HIF-1α
mediated mechanisms that provide ischemic cardioprotection; 3) evaluate the metabolic
changes in the heart as a result of HIF-1α expression.

17

CHAPTER 2
HIF-1α IN THE HEART: PROTECTIVE MECHANISMS
This work has been published in Wu et al., American Journal of Physiology, Heart and
Circulatory Physiology, volume 305 (6), H821-H828, 2013

SUMMARY
Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that directs many of the
cellular responses to hypoxia. In these studies, we have used a mouse model
containing a cardiac-specific, oxygen-stabilized, doxycycline (Dox-off) regulated HIF-1α
transgene to probe the role of HIF-1α in cardioprotection. Hearts used in these studies
were derived from wildtype (WT) mice, as well as those maintained on doxycycline to
suppress the HIF-1α transgene (Non-I) or denied doxycycline to express the HIF-1α
transgene for 2 days (2D) or 6 days (6D). Whereas HIF-1α protein is undetectable in
WT mouse hearts, it is present in heart tissue of Non-I transgenic mice, presumably
because of leakiness of the promoter construct. In mice denied doxycycline for 2 or 6
days, HIF-1α is overexpressed to a much greater extent than Non-I or WT animals, as
expected. WT and HIF-1α expressing hearts (Non-I, 2D and 6D induced) were
subjected to 30 minutes of ischemia, and functional recovery was measured upon
reperfusion. Recovery of pre-ischemic left ventricular developed pressure was 14% for
WT, 67% for Non-I hearts, 64% for 2D, and 62% for 6D hearts. 6D hearts have
increased pre-ischemic glycogen reserves, higher glycogen synthase protein levels, and
significantly higher lactic acid release during ischemia. 6D HIF hearts were also better
able to maintain ATP levels during ischemia compared with WT and Non-I hearts.
Interestingly, Non-I hearts showed no significant increase in glycogen reserves,
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glycolytic flux, or greater ATP preservation during ischemia and yet were protected to a
similar extent as the 6D hearts. Finally, the mitochondrial membrane potential of
isolated adult myocytes was monitored during anoxia or treatments with cyanide and 2deoxyglucose. HIF-1α expression was shown to protect mitochondrial polarization
during both stress treatments. Taken together, these data indicate that, while HIF-1α
expression in heart does induce increases in compensatory glycolytic capacity, these
changes are not necessarily required for cardioprotection, at least in this model of
ischemic stress.

INTRODUCTION
Hypoxia-inducible factor-1α (HIF-1α) is a master regulatory transcription factor
that directs the cellular response to hypoxia. When in vivo oxygen tension is sufficient,
HIF-1α is hydroxylated at proline residues 402 and 564 by a family of prolyl hydroxylase
domain-containing proteins (PHDs1–3) (2, 27). Hydroxylation of HIF-1α results in its
recognition by von Hippel-Lindau factor and its subsequent degradation via proteasomal
pathways. Hydroxylation of asparagine residue 803 (Asn803) by factor-inhibiting HIF
provides an additional regulatory mechanism for HIF-1α (10, 13). The hydroxylation of
Asn803 blocks the binding of coactivators CBP/p300 to the C-terminal activating domain
of HIF-1α, thereby limiting its transcriptional activity. Thus, HIF-1α is both stabilized and
its transcription activity is increased through these mechanisms when oxygen tension
drops. The present studies are designed to establish if HIF-1α is sufficient to confer
protection to the heart against ischemia-reperfusion injury and to begin to explore the
mechanisms through which this protection is afforded. In pursuit of these aims, we
used a transgenic mouse model containing a HIF-1α cDNA with alanine substitutions at
19

Pro402, Pro564, and Asn803 as described by Bekeredjian et al. (1). These
substitutions result in a HIF-1α protein, termed HIF-1α-PPN, that is stable and displays
full transcriptional activity in normoxic conditions. A tetracycline-regulated construct
was used to obtain regulation of transgene expression. In the presence of doxycycline,
transgene transcriptional expression is suppressed and induced when doxycycline is
excluded from the diet. The expression of the tetracycline transactivator protein is
driven by a cardiac-specific myosin heavy chain promoter, thus limiting HIF-1α
transgene expression to the cardiac myocytes in these animals.

HIF-1α was identified in kidney cells as the transcriptional inducer of the
erythropoietin gene (23, 24, 30). Subsequently, HIF-1α has been found to be
ubiquitously expressed and to regulate hundreds of genes involved in metabolism,
angiogenesis, and stress survival. One can view the changes directed by HIF-1α as
compensatory adaptations to an oxygen-deficient environment. For instance, HIF-1α
induces the expression of multiple glycolytic enzymes, including glucose transporter 1,
aldolase A, enolase 1, lactate dehydrogenase, phosphofructokinase, and
phosphoglycerate kinase (26). This upregulation of glycolysis decreases the cell's
reliance on oxidative phosphorylation for ATP. Most studies on HIF-1α have been
performed in cancer models, either cell lines or tumor tissue. Here HIF-1α has been
found to be a potent promoter of angiogenesis via its upregulation of vascular
endothelial growth factor and other angiogenic factors (25). More recently HIF-1α has
been ascribed the role as the primary driver of the Warburg effect, or the high rates of
aerobic glycolysis displayed by cancer cells (15). The close linkage between tumor
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growth and metastatic potential and the ability to attract vascularization explains the
intense interest in HIF signaling as it relates to cancer.

In heart, much less is known about the role of HIF-1α in pathophysiology.
Recently, prolonged overexpression of HIF-1α was shown to induce a cardiomyopathy
that was fully reversible upon cessation of HIF-1α expression. In the aforementioned
study, reduced sarco(endo)plasmic reticulum Ca2+-ATPase expression was linked to the
contractile dysfunction that was observed (1). In another study, cardiomyocytes treated
with prolyl hydroxylase inhibitors to induce HIF-1α reduce ATP turnover by 85%, with
the majority of these energy savings derived from attenuation of calcium
handling/contractile activities (29). These findings indicate that HIF-1α may be an
important driver of the dysfunction observed in ischemic heart disease. On the other
hand, evidence has begun to emerge that HIF-1α plays a central role in
cardioprotection. Ischemic preconditioning is a phenomenon where exposure of hearts
to short sublethal durations of ischemia-reperfusion provides protection from further
damage upon exposure to subsequent longer and normally lethal episodes of ischemic
stress. In a mouse model with a null allele of the HIF-1α locus resulting in less
expression of HIF-1α, a complete loss of preconditioning protection in heart was noted
(3). In another recent study, small-interfering RNA (siRNA) repression of HIF-1α was
found to attenuate preconditioning protection (6). Several reports have also shown that
the use of pharmacological prolyl hydroxylase inhibitors to induce HIF-1α levels confers
cardioprotection in several disparate cardiac model systems (19, 22, 28, 31). Similarly,
administration of siRNA, which targets PHD2 (16) or genetic models where PHD2 is
ablated, proves cardioprotective (17). Because PHDs have targets in addition to HIF21

1α, such as Iκkinase-1 (5), studies where PHD is inhibited do not necessarily prove HIF1α involvement. Nonetheless, taken together, these recent findings strongly indicate a
prominent role for HIF-1α in preconditioning and cardioprotection. Less clear are the
HIF-1α-induced mechanisms that are important in providing protection from ischemiareperfusion injury in heart. In these studies, we compare the ischemic stress tolerance
of hearts that are induced to express HIF-1α-PPN in varying amounts and durations to
begin to probe the aforementioned questions.

EXPERIMENTAL PROCEDURES
Reagents: Sterile oxyrase was purchased from Oxyrase (Mansfield, OH).
Tetramethylrhodamine (TMRM) was purchased from Life Technologies (Grand Island,
NY). 2,3,5-Triphenyl-2H-tetrazolium chloride (TTC) was obtained from Tokyo Kasei
Kogyo (Tokyo, Japan). Rabbit polyclonal primary antibody against HIF-1α was obtained
from Novus Biologicals (Littleton, CO), whereas rabbit monoclonal primary antibody
against glycogen synthase was obtained from Cell Signaling (Danvers, MA). Goat antirabbit secondary antibodies were purchased from Millipore (Billerica, MA) and Cell
Signaling. Doxycycline hydrochloride was purchased from RPI (Mount Prospect, IL).

Animal model: B6C3F1 mice containing the HIF-1α-PPN transgene have been
previously described by Bekeredjian et al. (1). All mice used were males between 2 and
3.5 months of age and were routinely maintained on a 625 mg/kg doxycycline-replete
diet (Harlan Research Laboratories, Madison, WI). In experiments requiring 2 days of
HIF-1α expression (2D), mice were switched from doxycycline food to doxycyclinereplete water containing 73 mM sucrose (Mallinckrodt Baker, Phillsburg, NJ) and 0.416
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mM doxycycline hydrochloride for 2 days followed by maintenance of mice on regular
food and water for two additional days. In experiments requiring 6 days of HIF-1α
expression (6D), mice were maintained on doxycycline-free food and water for 5–7 days
before experimentation. Wildtype (WT) B6C3F1 mice were obtained from Harlan.
Animals were handled in accordance to a protocol reviewed and approved by the East
Tennessee State University Committee on Animal Care.

Isolation of cardiomyocytes from adult mice: Myocytes from adult mice hearts
were isolated according to procedures described by O'Connell et al. (18). Isolated
myocytes were suspended in 10 ml of plating medium with 25 µM blebbistatin and
incubated on plates that were precoated with matrigel (BD Biosciences, Rockville, MD)
diluted 1:40 in DMEM-F-12 (GIBCO, Grand Island, NY) for 1 hour in 5% CO2. After
incubation in plating medium, myocytes were maintained on culture medium with 25 µM
blebbistatin. Experiments using adult mice cardiomyocytes were performed on the
same day as cell isolation.

Preparation of mice heart homogenates: Hearts from wildtype (WT), noninduced (Non-I), 2D, and 6D mice were excised and washed briefly in PBS to remove
excess blood. Hearts were then immediately clamped with a set of tongs that were prechilled in liquid nitrogen. They were then ground into a fine powder using a mortar and
pestle under liquid nitrogen. The powdered heart tissue was homogenized in RIPA
buffer composed of 50 mM TrisHCl, pH 7.4 (Calbiochem, Darmstadt, Germany), 1% v/v
Triton X-100 (Fisher, Pittsburgh, PA), 1% w/v sodium deoxycholate (Fisher), 0.1% w/v
SDS (EMD, Billerica, MA), and 1 mM EDTA (Fisher) with 1:40 protease inhibitor cocktail
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mix (Sigma, St. Louis, MO). The homogenates were centrifuged at 12,000 g at 4°C for
10 minutes. The supernatant was collected. Protein concentration for the supernatant
was determined using the Pierce BCA protein assay kit from Thermoscientific
(Rockford, IL) according to the manufacturer's protocol.

SDS-PAGE and western blot: HIF-1α and glycogen synthase expression were
evaluated using standard SDS-PAGE and Western blotting techniques. Protein
samples were separated using SDS-PAGE in Pierce Tris-HEPES-SDS 4–20% precast
polyacrylamide gels (Thermoscientific). Proteins were transferred to polyvinylidene
difluoride membranes (BioRad, Richmond, CA) at 75 volts for 2 hours. After transfer,
Ponceau S (Sigma) staining was used to ensure complete transfer and equal protein
loading. Membranes were blocked in 5% nonfat dry milk in TBS with 0.1% Tween 20
(TBS-T) for 1 hour at room temperature. HIF-1α expression was probed using a rabbit
polyclonal primary antibody diluted 1:500 in TBS-T, and glycogen synthase expression
was probed with a rabbit monoclonal primary antibody at 1:1,000 dilution in TBS-T.
Both membranes were incubated at 4°C overnight and washed for 5 minutes in TBS-T
(5x) before incubation with goat anti-rabbit horseradish peroxidase-conjugated (HRP)
secondary antibody. Protein bands were detected using the Pierce supersignal
chemiluminescence substrate (Thermoscientific) in the G:Box fluorescence and
chemiluminescence imaging system (Syngene, Frederick, MD). Densitometry was
performed using ImageJ (National Institutes of Health, Bethesda, MD).

Langendorff perfusion: Hearts were retrograde perfused through the aorta with
Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8
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NaHCO3, 2.5 CaCl2, and 10.6 glucose. The buffer was equilibrated with 95% O2 and
5% CO2 and maintained at 37°C. A fluid-filled silicon balloon was inserted in the left
ventricle through the mitral valve for left ventricular developed pressure (LVDP)
measurement with a pressure transducer (AD Instruments, Dunedin, New Zealand).
Balloons were fabricated using methods previously published (14). Hearts were
allowed to stabilize during a 25 minute baseline period after which, function, tissue
viability, lactate accumulation, ATP, and ADP levels were evaluated after hearts had
been subjected to various ischemia-reperfusion protocols. For measurement of lactate
production during ischemia, the perfusate during the first 5 minutes of reperfusion was
collected. Lactate content was measured colorimetrically (450 nm) in a 96-well plate
format following instructions from the Biovision lactate assay kit (Biovision, Milpitas,
CA).

Evaluation of tissue viability after ischemia-reperfusion: After the initial
stabilization period, hearts were subjected to 30 minutes of ischemia and 60 minutes of
reperfusion. At the end of the protocol, the hearts were perfused with 1% TTC and then
taken off the cannula to incubate for 15 minutes at 37°C. Afterwards, the hearts were
sliced transversely, and images of the transverse slices were taken using a Microtek
film scanner (Microtek International, Hsinchu, Taiwan). The viable (stained dark
orange) and non-viable (unstained yellow) sections were analyzed using Adobe
Photoshop (Adobe Systems, San Jose, CA).

Measurement of pre-ischemic glycogen reserves: For glycogen content, frozen
powdered heart tissue was transferred to an Eppendorf tube and 500 µl of ddH2O was
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added. The samples were immediately boiled for 5 minutes and centrifuged at 13,000
RPM. Protein concentration was determined using the Pierce BCA assay kit
(Thermoscientific). Glycogen content was measured colorimetrically at 570 nm on a 96well plate format following instructions provided with the Biovision glycogen assay kit
(Biovision).

Measurement of nucleotides: ATP and ADP measurements in hearts subjected
to ischemia were done using high-performance liquid chromatography (HPLC) following
a method established by Giannattasio et al. (7). At the end of the respective perfusion
protocol (pre-ischemic, 5, 10, 20, or 30 minutes of ischemia; or 30 minutes of ischemia
followed by 30 minutes of reperfusion), hearts were freeze-clamped and then pulverized
to a fine powder using a mortar and pestle. Next, the frozen heart tissue was
homogenized in 400 µl of 4% perchloric acid (Alfa Aesar, Ward Hill, MA) to extract
nucleotides. The homogenate was incubated on ice for 20 minutes. Following
incubation, the homogenate was centrifuged at 15,000 g for 15 minutes at 4°C. The
supernatant containing total nucleotides was collected and stored in −80°C until further
processing. The remaining tissue pellet was lyophilized to obtain the dry tissue weight.

Before measurement of ATP and ADP on HPLC, the samples containing total
heart nucleotides were neutralized in a solution consisting of 4/5 volume 2 M KOH
(Fisher) and 1/5 volume 1 M KH2PO4 (MP Biomedical, Solon, OH). After neutralization,
the samples were incubated on ice for 10 minutes and centrifuged for 15 minutes at
15,000 g at 4°C. The resulting supernatant was collected and filtered through a 0.22µm syringe filter (Millipore).
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HPLC runs were performed using a binary gradient with increasing organic
strength. The binary gradient was programmed into the LCsolutions data acquisition
software (Shimadzu Scientific Instruments, Columbia, MD). The mobile phases were
buffer A, which consists of 8 mM tetrabutylammonium hydrogen sulfate (Acros Organic,
Morris Plains, NJ) and 0.1 M KH2PO4 (MP Biomedical). Buffer B consists of 8 mM
tetrabutylammonium hydrogen sulfate (Acros Organic) and 0.1 M KH2PO4 (MP
Biomedical) with the addition of 30% CH3CN (Fisher). Both mobile phase buffers were
pH to 6. Sample (100 µl) was injected into a 20-µl loop, and peak detection was done
using the SPD-M20A diode array detector at 254 nm (Shimadzu Scientific Instruments)
and recorded with the LCsolutions data acquisition software. The areas of the peaks
corresponding to ATP and ADP were integrated using the LCsolutions postrun analysis
program (Shimadzu Scientific Instruments). Total ATP and ADP content expressed in
units of µmole was calculated from the respective calibration curves and normalized
against the amount of dry tissue collected (grams).

Measurement of mitochondrial membrane potential during anoxia and metabolic
inhibition: Adult mice cardiomyocytes were plated on 50-mm MatTek dishes (MatTek,
Ashland, MA) and incubated in 1.5 ml of culture medium as described by O'Connell et
al. (18) with 200 nM TMRM at 37°C and 5% CO2. After 30 minutes of incubation in 200
nM TMRM, the culture medium was substituted with 50 nM TMRM in PBS plus 5 mM
glucose and 10 mM succinate. Before imaging, a cover slip was placed over the cells,
and 15 µl of sterile oxyrase were added. Oxyrase selectively removes oxygen, creating
depletion of oxygen in the cardiomyocyte's immediate surroundings. Fluorescent
imaging was performed on the Zeiss Axio Observer Z1 inverted fluorescent microscope
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(Zeiss, Gottingen, Germany). Images for cardiomyocytes from all mice groups were
captured using the Zeiss AxioCam MRm monochrome digital camera (Zeiss) at t0, the
time point immediately after culture medium was substituted with PBS plus 5 mM
glucose, 10 mM succinate, and 50 nM TMRM. Subsequent images were captured after
0.5, 1, 1.5, and 2 hours of incubation with oxyrase. Images were analyzed with the
Zeiss AxioVision 4.8.2 software. The number of polarized myocytes (i.e., those
exhibiting TMRM fluorescence) was counted at each time point of oxyrase incubation
and was expressed as a percent of polarized myocytes prior to anoxia. For
measurement of mitochondrial membrane potential during inhibition of oxidative
phosphorylation and glycolysis, isolated myocytes were incubated with 200 nM TMRM
in culture medium for 30 minutes. After this period, culture medium was replaced with
PBS plus 50 nM TMRM, 2 mM sodium cyanide (Mallinckrodt Baker), and 5 mM 2deoxyglucose (2-DG; Acros), and a series of fluorescent images were taken at 0, 15,
30, 45, and 60 minutes of incubation. The number of polarized rod-shaped cells at each
incubation time point (i.e., those displaying TMRM fluorescence) was counted and
expressed as a fraction of polarized cells prior to cyanide and 2-deoxyglucose
treatment.

Statistical analysis: Data reported here are expressed as means±SEM.
Statistical analysis was performed using one-way ANOVA followed by StudentNewman-Keuls post hoc testing using GraphPad Prism 5 (La Jolla, CA).

RESULTS
HIF-1α-expressing hearts tolerate ischemia better.
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Hearts derived from WT and transgenic animals induced to express HIF-1α for
the indicated times were retrograde perfused and subjected to 30 minutes of ischemia
followed by reperfusion to allow recovery. No differences in the spontaneous beating
rate or LVDP were noted between HIF-1α-expressing and control hearts before
ischemia. Upon cessation of perfusion, the ischemic contracture was found to be more
slowly developing and of a lower ultimate magnitude in 2D- and 6D-induced HIF-1α
hearts (Figure 2.1). Recovery of function following ischemia was remarkably higher in
Non-I, 2D, and 6D HIF-1α-induced hearts compared with WT hearts (Figure 2.2A). The
magnitude of ischemic contracture was significantly lower for 2D-induced and 6Dinduced hearts, but not Non-I hearts, compared with the WT hearts (Figure 2.2B).

Next, tissue viability after the ischemic challenge was assessed using TTC
staining. Tissue viability was found to correlate well with the enhanced functional
recovery of the hearts (Figure 2.3, A and B). Somewhat surprisingly, the recovery of
pre-ischemic LVDP and tissue viability of HIF-1α-PPN Non-I hearts was equivalent to
the 2D-induced and 6D-induced hearts (Figures 2.2 and 2.3). This finding caused us to
examine the possibility of HIF-1α-PPN “leakage” in the hearts of animals maintained on
a doxycycline-replete diet. Indeed, we find that, while Non-I heart extracts contain far
less HIF-1α protein than their induced counterparts, they do have higher levels than WT
hearts (Figure 2.3C). Perhaps this should not have been unexpected given that HIF-1αPPN has been modified to be stable under normoxic conditions via the substitution of
critical amino acids within its degradation domain. Thus, any small expression leakage
will result in some accumulation of the stable HIF variant. The results indicate that,
while HIF-1α-PPN expression is much lower in the Non-I hearts, it is sufficient to protect
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to a similar extent, at least against this stress protocol. In contrast, the moderation of
ischemic contracture appeared to require the higher, induced levels of HIF-1α (Figure
2.2B).

HIF-1α causes glycogen synthase induction, glycogen accumulation, and
increased glycolytic flux during ischemia.
Because ischemic contracture has been reported to be delayed and reduced in
magnitude by higher glycogen reserves, we next examined the effects of HIF-1α
expression on glycogen levels in the HIF-expressing and WT hearts. Although a trend
was observed for higher glycogen reserves in all the hearts expressing HIF-1α-PPN,
only the 6D HIF-induced mouse hearts had significantly higher levels of glycogen stores
compared with WT and Non-I hearts (Figure 2.4A). Given the higher glycogen stores at
the initiation of ischemia, we sought to estimate the glycolytic flux during the 30 minutes
of no-flow ischemia. Accordingly, the next experiment measured the lactic acid
accumulated during the 30 minutes of ischemia that is released during the first 5
minutes of reperfusion (Figure 2.4B). As with glycogen stores, lactic acid release was
significantly elevated in the 6D HIF-induced hearts compared with hearts from WT and
the Non-I HIF-1α-PPN mice. Recent reports indicating that glycogen synthase is a HIF1α-responsive gene might explain the higher levels of glycogen stores in the HIFexpressing hearts. Consistent with this, we find significantly elevated glycogen
synthase protein levels in HIF-1α-PPN transgenic mice hearts (Figure 2.4C).
Interestingly, glycogen synthase protein levels are elevated to a similar extent in Non-I
hearts as those induced for 2 and 6 days. The discrepancy between glycogen synthase
and glycogen levels among the experimental groups probably reflects the complex array

30

of factors that ultimately determine tissue glycogen levels. Nonetheless, these results
showing that HIF-1α directs induction of glycogen synthase and glycogen accumulation
in adult heart are important findings. Given that glycogen granule accumulation is a
hallmark of the hibernating myocardium (9), it indicates that HIF-1α may be a driver of
this pathophysiological phenotype.

The upregulation of glycolytic metabolism does not explain the protection
afforded by HIF-1α.
The well-known ability of HIF-1α to induce many of the enzymes that comprise
the glycolytic pathway when coupled to elevated glycogen stores suggests an obvious
avenue to achieve the cardioprotection observed in the HIF-1α-PPN hearts.
Mobilization of the glucose stores, and enhanced glycolysis and its attendant ATP
production during stoppage of perfusion, is consistent with the moderation of ischemic
contracture and increased lactic acid release that we observe in HIF-expressing hearts.
To address the issue of glycolytically produced ATP moderating the contracture and the
damage sustained during ischemia, hearts were flash-frozen at intervals during
ischemia and extracted, and nucleotide contents were measured with HPLC. Examples
of HPLC chromatograms showing nucleotides and their metabolites are provided in
Figure 2.5. Hearts derived from 2D- and 6D-induced HIF-1α-PPN hearts maintained
significantly elevated levels of ATP at 20 and 30 minutes of ischemia compared with WT
control hearts (Figure 2.6A). Among the experimental groups, only 6D-induced HIF-1αPPN hearts maintained significantly elevated ATP:ADP ratio at any time point of
ischemia (Figure 2.6B). The comparison of ATP depletion between Non-I HIF-1α-PPN
and WT hearts showing no differences in the degree of ATP depletion is most
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interesting given the high degree of ischemic tolerance the Non-I hearts display. These
findings call into question the relative importance of the compensatory increases in
glucose stores and glycolytic enzymes in the protective phenotype of the HIF-1α-PPN
hearts. Other mechanisms besides increasing glycolytic flux during ischemia are
suggested to be employed by HIF-1α to protect the myocardium. The next series of
experiments were designed to begin to probe alternative mechanisms of protection.

Previously, we found that the ability of mitochondria to maintain polarization
during simulated ischemia is strongly associated with protection in the heart cell (29).
Thus, we tested whether isolated adult cardiomyocytes from HIF-1α-PPN hearts also
display improved mitochondrial function under similar conditions. Adult cardiomyocytes
were isolated from WT, Non-I, 2D- and 6D-induced HIF-1α-PPN hearts and subjected to
anoxia. Mitochondrial polarization was monitored with TMRM potentiometric dye for 2
hours under these conditions. We find that HIF-1α-PPN myocytes maintained
mitochondrial polarization in significantly greater numbers than WT cells, with 6Dinduced cardiomyocytes performing best, being little affected over the 2 hour period
(Figure 2.7). In the next experiment, the dependency of protection on enhanced
glycolytic flux was directly addressed. Myocytes derived from WT, Non-I, 2D- and 6Dinduced HIF-1α-PPN hearts were treated with cyanide and 2-DG to block both oxidative
phosphorylation and glycolysis, and mitochondrial polarization was followed for 1 hour.
We find that HIF-1α-expressing myocytes are able to maintain mitochondrial membrane
potential under these conditions to a significantly greater extent than WT myocytes
(Figure 2.8). This finding causes us to conclude that the well-known compensatory
increase in glycolytic capacity that is induced by HIF-1α is not necessary for the
32

ischemic tolerance conferred by HIF-1α and points to the existence of additional
mechanisms that center on the mitochondrion.

DISCUSSION
Twenty years after its discovery, HIF-1α is well established to play a central role
in the cellular response to hypoxia; however, much less is known about its
cardiospecific effects. In these studies, we show that forced expression of a stabilized
mutant version of HIF-1α confers robust protection to adult heart in a common ex vivo
model of ischemia-reperfusion injury. Given the prominence of ischemic stress in the
constellation of pathologies grouped under the umbrella of heart disease, it is of great
interest to understand the mechanisms the cardiomyocyte employs to protect itself
against hypoxia stress. Certainly HIF's actions in protecting the myocyte from
irreversible damage during ischemia can be regarded as beneficial. On the other hand,
evidence also exists that ascribes a pathological role to HIF-1α in the context of
decreased myocardial function during chronic hypoxia such as occurs in ischemic heart
disease. Indeed HIF's pathological and protective mechanisms are likely to overlap, in
that decreased function and lower ATP turnover represent powerful protective
maneuvers when oxygen becomes limited (11, 12). In this vein, we should note that
HIF-1α-PPN induction for up to 6 days did not change the basal contractile
characteristics (i.e., LVDP when paced, or spontaneous heart rate, data not shown) of
mice hearts when they were examined ex vivo with Langendorff perfusion. Thus, the
robust ischemic protection afforded by HIF-1α expression was not accompanied by any
indication of pathological response in the time frames examined in this study.
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The most prominent effect of HIF-1α-PPN expression on the response of the
perfused heart to 30 minutes of ischemia is an attenuated ischemic contracture.
Sometimes referred to as “stone heart,” the underlying mechanisms governing
contracture are not completely understood (8). Initiation of contracture is closely tied to
the rate of ATP depletion and exhaustion of internal glycogen stores (8). It is important
to note, however, that the severity of ischemic contracture does not correlate with
myocardial protection or recovery of function in heart. This is best illustrated by the fact
that ischemic preconditioning, which is highly protective, shortens the time until onset of
contracture probably through depletion of glycogen stores. This has led to the
suggestion that glycogen and high rates of glycolysis and acidification during ischemia
are detrimental to cellular recovery. The degree of severity and length of the ischemic
insult probably determine whether mobilization of glycogen stores and glycolytic ATP
production are effectively beneficial or detrimental to tissue viability (4). For instance,
with chronic low-flow ischemia, enhanced glycolytic ATP generation greatly improves
functional outcomes.

Recently, muscle glycogen synthase was shown to be a HIF-1α-inducible gene in
C2C12 skeletal muscle myotubes and several cell lines (21). Our results show that HIF1α elevates glycogen synthase in adult heart cells and leads to glycogen accumulation,
especially in 6D HIF-1α-induced hearts, where significant elevations of glycogen
synthase, glycogen, and lactic acid production during ischemia were noted. Of
importance, the enhanced glycolysis was reflected in a significant diminishment of ATP
depletion in the 6D-induced hearts during ischemia. The finding that HIF-1α is sufficient
to cause glycogen accumulation in the adult myocardium is also of significance.
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Glycogen accumulation is a hallmark of hibernating myocardium. Given previous
findings that HIF-1α suppresses oxidative phosphorylation (20), ATP turnover, and
contractile function (29), a strong circumstantial argument can be made that HIF-1α may
play a large role in directing the hibernating phenotype in heart. As mentioned above,
however, we were unable to detect any changes in contractile function or oxidative
respiration in 6D HIF-induced hearts. Specifically, LVDP, dP/dt, and O2 consumption
were measured in WT, Non-I, and 2D- and 6D-induced hearts, whereas pacing was
increased in 200-beat/minute step increments from 300 to 1,300 beats/minute. No
significant changes in these parameters were found between the hearts in any of the
experimental groups (data not shown). We are presently uncertain why HIF-1αexpressing hearts fail to show any evidence of reduced oxidative phosphorylation (29)
or contractile function (1) noted in other model systems. Several possible explanations
are currently being tested but are beyond the scope of these studies, which have
focused upon the protective effects of HIF-1α-directed changes.

In these studies, we have exploited our inducible HIF-1α-PPN transgenic system
to provide something akin to the dose-response curve, where the influence of HIF-1α is
absent in the wildtype: < in Non-I << 2D-induced < 6D-induced derived hearts. This
pseudo dose-response yielded interesting insights into the biology of the compensatory
responses elicited by HIF-1α. We examined pre-ischemic glycogen reserve, glycolytic
activity, and ATP depletion kinetics during ischemia in WT, Non-I, and 2D- and 6Dinduced mice hearts. We found that the Non-I HIF-1α-PPN hearts did not show
significant increases in pre-ischemic glycogen store, glycolytic flux during 30 minutes of
ischemia, or increased ability to maintain ATP levels during various times of ischemia
35

compared with WT hearts. Nonetheless, Non-I hearts were protected to the same
extent as hearts induced to express HIF-1α for 2 and 6 days. This suggests that, while
increasing glycogen reserves before, and glycolytic flux during, ischemia clearly
represent a compensatory response; it may not comprise the primary mechanism of
protection to the total global ischemia employed in these studies.

Similar to these studies, our work examining the cardioprotective mechanisms of
the O2 sensor in neonatal cardiomyocytes called into question the central importance of
the induction of glycolytic capacity and glycogen accumulation in protection (28). In
previous work, we found that HIF-1α expression, albeit as the result of
dimethyloxalylglycine treatment rather than genetic manipulation, led a persistent ability
to maintain mitochondrial polarization during anoxia or cyanide poisoning, even when
glycolysis was blocked or the reverse mode of ATP synthase was inhibited. After
extensive analysis, we ultimately concluded that fumarate was used as an alternate
terminal electron acceptor to allow electron flux to continue through complex I during
anoxia or cyanide poisoning (29). In the studies shown in Figure 2.7 and Figure 2.8
isolated adult heart cells were tested in vitro to determine whether the protection
observed in HIF-expressing hearts would translate into stabilized mitochondrial
polarization during anoxia. In both anoxic conditions permissive for glycolysis, and in
conditions where both oxidative phosphorylation and glycolysis are blocked (cyanide
and 2-DG present), mitochondrial membrane potential was significantly better
maintained in the HIF-1α-expressing cardiomyocytes. Taken together, these results
reveal that HIF-1α can provide ischemic cardioprotection via mechanisms independent
of compensatory increases in glycolytic flux and ATP preservation. Studies are
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underway to quantitatively measure the flux through fumarate respiratory pathways that
HIF-1α induces.

Clearly HIF-1α is initiating a complex multifactorial compensatory program that
equips the adult cardiomyocyte with remarkable tolerance to hypoxic stress. The most
well-known HIF-1α-driven response to hypoxia is the induction of glycolytic pathway
enzymes (25). Our data confirm that glycolytic capacity is increased by HIF-1α in adult
murine cardiomyocytes and that this reserve is tapped during acute ischemia.
Somewhat surprising, the findings also call into question the central importance of this
increased glycolytic capacity as the central mechanism leading to the powerful
protection conferred by HIF-1α in the acute no-flow ischemic protocol that we employ.
Rather, isolated cell studies implicate mechanisms that preserve mitochondrial function
during ischemia in the powerful cardioprotection that is observed.
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FIGURES

Figure 2.1: Response of murine hearts with varying degrees of hypoxia-inducible factor-1α
(HIF-1α) expression to 30 minutes of ischemia, followed by reperfusion. Shown are exemplary
condensed pressure tracings from Langendorff-perfused hearts derived from wildtype (WT) and
HIF-1α-PPN mice that were not induced (Non-I) and induced to express HIF-1α for 2 days (2D
induced) or 6 days (6D induced). Hearts were subjected to 30 minutes of ischemia following
pre-equilibration for at least 20 minutes, whereupon they were allowed to recover. In some
hearts, the left ventricular balloon was deflated during ischemia and reperfusion. In the example
shown here, the balloon was allowed to remain inflated so that ischemic contraction could be
measured. LVDP, left ventricular developed pressure.
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Figure 2.2: Quantification of cardiac functional recovery after ischemia of the experiment shown
in Figure 2.1. A: recovery of LVDP after 30 minutes of ischemia. B: ischemic contracture
expressed as a percent of basal LVDP. *P < 0.05 vs. WT; n = 6–8 hearts.
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Figure 2.3: HIF-1α expression limits myocardial ischemic damage. A: typical
triphenyltetrazolium chloride (TTC) staining pattern in WT, non-induced, 2D-induced, and 6Dinduced mouse hearts post-ischemic reperfusion insult; note that viable tissue stains a darker
orange color. B: viable tissue was determined by TTC staining in perfused hearts following 30
minutes of ischemia and 60 minutes of reperfusion. The percent viable tissue was quantified
using images of transverse sections of heart ventricles and Adobe Photoshop software. *P <
0.05 vs. WT. C: representative Western blot showing HIF-1α protein levels in protein extracts
from hearts in the indicated treatment groups.
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Figure 2.4: Glycogen reserves are increased in HIF-1α-expressing hearts. A: measurement of
glycogen content in WT, non-induced, 2D-induced, and 6D-induced mouse hearts (n = 4
hearts). B: accumulated lactate was measured in the perfusion buffer effluent collected during
the initial 5 minutes of reperfusion after 30 minutes of ischemia. C: Western blot showing
glycogen synthase protein levels in WT, non-induced, 2D-induced, and 6D-induced mouse heart
extracts. D: densitometry analysis of the glycogen synthase protein band intensity from the
Western blot experiment shown in C (n = 4). *P < 0.05 vs. WT. #P < 0.05 vs. non-induced.
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D

Figure 2.5: Examples of HPLC chromatograms showing the content of adenine nucleotides,
nucleosides, and nucleobases in mouse hearts. A: pre-ischemic
ischemic wildtype mouse heart. B:
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pre-ischemic 6 day HIF-1α induced (6D) mouse heart. C: wildtype mouse heart after 30
minutes of ischemia. D: 6 day HIF-1α induced (6D) mouse heart after 30 minutes of ischemia.
Peaks: (1) hypoxanthine {RT=5.05 minutes}, (2) xanthine {RT=5.34 minutes}, (3) inosine
{RT=8.02 minutes}, (4) IMP {RT=8.89 minutes}, (5) adenosine {RT=12.66 minutes}, (6) AMP
{RT=13.32 minutes}, (7) ADP {RT=18.40 minutes}, (8) ATP {RT=22.49 minutes}. RT stands for
retention time for the indicated peak.

Figure 2.6: ATP levels are better maintained during ischemia in hearts where HIF-1α
expression has been induced. Hearts were freeze-clamped and extracted at the indicated time
points of ischemia. ATP and ADP levels were measured by reverse-phase HPLC (see
experimental procedures). A: ATP content in hearts subjected to increasing durations of
ischemia. ATP levels are expressed as a percentage of pre-ischemic values within all
experimental groups. Pre-ischemic ATP values were 26.4 ± 3.7, 27.7 ± 8.7, 19.4 ± 11.2, and
21.4 ± 2.4 µmole/g dry tissue in WT, non-induced, 2D-induced, and 6D-induced mouse hearts,
respectively. B: the ATP-to-ADP ratio expressed as a percentage of the pre-ischemic values,
which are 3.3 ± 0.6, 4.5 ± 1.0, 4.8 ± 0.3, and 3.1 ± 0.6 for WT, non-induced, 2D-induced, and
6D-induced mouse hearts, respectively. The data represent means±SEM (n = 3–9). *P < 0.05
vs. WT.
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Figure 2.7: Mitochondrial membrane polarization is better maintained in HIF-1α-expressing
adult cardiomyocytes during anoxia. A: typical TMRM fluorescent image of WT, non-induced
(Non-I), 2 day-induced (2D), and 6 day-induced (6D) mouse heart cardiomyocytes after 0, 0.5,
1, 1.5, and 2 hours of anoxia. B: cells with polarized mitochondria relative to the amount before
anoxia expressed as means±SEM (n = 3–8). *P < 0.05 vs. WT.
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Figure 2.8: HIF-1α-expressing cardiomyocytes maintain polarized mitochondria when both
oxidative phosphorylation and glycolysis is blocked. A: representative TMRM fluorescent
images of cardiomyocytes obtained from WT, Non-I, 2D-induced, and 6D-induced mice after 0,
15, 30, 45, and 60 minutes of cyanide (CN−) and 2-deoxyglucose (2-DG) treatment to block
oxidative phosphorylation and glycolysis, respectively. B: number of rod-shaped cells with
polarized mitochondria relative to the amount prior to cyanide and 2-DG treatment expressed as
means±SEM (n = 3). *P < 0.01 vs. WT.
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CHAPTER 3
HIF-1α IN THE HEART: EXPRESSION OF PURINE NUCLEOTIDE CYCLE
ENZYMES
SUMMARY
Previous studies have shown that activation of HIF-1α signaling conferred the ability for
cardiomyocytes to use fumarate as an alternative terminal electron acceptor to sustain
anoxic mitochondrial electron transport chain (ETC) activity. Further investigations
revealed that the source of fumarate was the nucleotide metabolic pathway known as
the purine nucleotide cycle (PNC). In those studies, HIF-1α signaling was induced via
treatment with prolyl hydroxylase (PHD) inhibitor dimethyloxaloylglycine (DMOG).
However, as PHD activates pathways in addition to HIF-1α, the direct effect of HIF-1α
on PNC activity cannot be established. Here, we utilized wildtype mouse hearts and
hearts in which HIF-1α is overexpressed to establish whether HIF-1α directly induces
the enzymes in the PNC. We report that HIF-1α induces the entry point of the PNC,
AMP deaminase 2 (AMPD2) while not affecting downstream reaction steps
adenylosuccinate synthetase (ADSS) and adenylosuccinate lyase (ADSL). During
ischemia, the inability for glycolysis to meet ATP demands of the heart leads to an
imbalance between ATP consumption and ATP synthesis. Thus, ATP in the heart is
depleted and AMP accumulates. AMP can be metabolized by AMP deaminase to IMP.
Subsequent cycling of IMP through the PNC regenerates AMP. Thus, the PNC acts as
a conservation pathway for the heart's nucleotide pool. The induction of glycolysis in
conjunction with the PNC by HIF-1α may preserve the heart's adenine nucleotide
resources during ischemic insult. These considerations provide the motivation for us to
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pursue a full understanding of how HIF-1α influences nucleotide metabolism in the
ischemic heart and results will be presented in the next chapter.
INTRODUCTION
Studies pioneered by Peter Hochachka demonstrated that succinate is a major
metabolic end product associated with anoxia (3, 4). Mechanisms leading to succinate
production via the conversion of succinyl-CoA and reduction of fumarate have been
proposed by Hochachka (Figure 3.1) (3). Studies by Weinberg et al., Hohl et al., and
Sridharan et al. have demonstrated that in kidney and cardiomyocytes, succinate
synthesis under anaerobic conditions occurs mainly via fumarate reduction at
mitochondrial complex II as indicated in Figure 3.1 (5, 10, 12).

Sridharan et al. demonstrated that activation of the HIF-1α signaling cascade in
neonatal mice cardiomyocytes, albeit via treatment with prolyl hydroxylase inhibitor
DMOG, led to enhanced succinate production during anoxia (10). These studies led to
the unexpected finding that aspartate transamination as proposed by Hochachka (3)
was not the source of fumarate used for succinate synthesis. The source of fumarate
instead, was the nucleotide metabolic pathway known as the purine nucleotide cycle
(PNC; see Figure 3.2). As ATP is depleted during anoxic stress, AMP accumulates.
The series of reactions in the PNC starts when AMP is converted to IMP by AMP
deaminase (Figure 3.2). IMP is subsequently metabolized by adenylosuccinate
synthetase, an enzyme that uses aspartate as a co-factor to generate S-AMP (Figure
3.2). Hochachka observed that anoxia leads to a depletion in cellular aspartate (3).
From studies conducted by Sridharan et al., it is clear that the decrease in aspartate is
due to its metabolism by adenylosuccinate synthetase (10). S-AMP is finally
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metabolized by adenylosuccinate lyase to produce AMP and fumarate (Figure 3.2).
Those cardiomyocytes treated with DMOG were able to initiate electron transfer by
oxidizing NADH at complex I (Figure 3. 2). The resulting electron is then taken up by
fumarate at complex II, which acts as the terminal electron acceptor in place of oxygen.
This mechanism leads to the synthesis of succinate and the continual pumping of H+
from the mitochondrial matrix into the intermembrane space, thus allowing DMOG
treated cardiomyocytes to maintain mitochondrial polarization during anoxia, leading to
tolerance from anoxic stress (10).
Results presented in chapter 2 provide evidence that HIF-1α confers in
cardiomyocytes, the ability to maintain mitochondrial polarization during ischemia.
Studies conducted by Sridharan et al. demonstrated that HIF-1α may induce PNC
activity (10). In those studies performed by Sridharan et al., HIF-1α signaling was
activated via inhibition of prolyl hydroxylases (10). Prolyl hydroxylases target pathways
in addition to HIF-1α (2). The aim in this portion of our studies is to examine the
expression of PNC enzymes in wildtype and HIF-1α expressing hearts in order to
determine whether HIF-1α directly induces the expression level of PNC enzymes.
EXPERIMENTAL PROCEDURES

AMP deaminase (AMPD) mRNA expression: RNA was extracted from wildtype
mouse hearts (Harlan Research Laboratories, Madison, WI) and HIF-1α-PPN Non-I, 2D,
and 6D mouse hearts using TRIzol reagent (Life Technologies, Carlsbad, CA). RNA
concentration as well as integrity were determined using the Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA). cDNA was synthesized using the Superscript
III cDNA synthesis kit (Life Technologies). For each cDNA synthesis reaction, 2 µg of
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RNA was added to 1.25 µM oligo(dT)20, 50 ng random hexamers, 0.5 mM dNTP mix, 80
U RNaseOUT, 5 mM DTT, 1.25 mM MgCl2, and 400 U reverse transcriptase in a final
volume of 40 µl. The cDNA synthesis reaction was allowed to proceed for 1 hour at
50oC and then terminated by heating at 70oC for 15 minutes. Quantitative PCR was
performed in triplicate for all samples in a 96 well plate format on the CFX96 real-time
PCR detection system (BioRad Laboratories, Richmond,CA). 40 cycles were carried
out. Each reaction consisted of 50 ng cDNA and1.5 µl of Quantitect AMPD2 or
transferrin primer from Qiagen in 1x SsoFast Evagreen supermix (BioRad Laboratories).
AMPD2 mRNA expression was normalized to that of reference gene transferrin and
results were reported as a percent change in gene expression relative to wildtype.
Protein expression of PNC enzymes: Protein samples from WT and HIF-1α-PPN
Non-I, 2D, and 6D mouse hearts were prepared according to methods detailed in
chapter 2. AMPD2 was probed using a mouse monoclonal primary antibody diluted
1:1000 in TBS-T (Abcam, Cambridge, MA). ADSS was probed using a rabbit polyclonal
antibody against ADSS diluted 1:1000 in TBS-T (Proteintech Group, Inc., Chicago, IL).
The membranes were incubated in primary antibody at 4°C overnight. After incubation
in primary antibody, the membranes were washed for 5 minutes in TBS-T (5x) before
incubation with 1:5000 rabbit anti-mouse horseradish peroxidase conjugated secondary
antibody for AMPD2 (Abcam) or 1:5000 goat anti-rabbit secondary for ADSS (EMD).
Protein bands were detected using the Pierce supersignal chemiluminescence
substrate (Thermoscientific) in the G:Box imaging system (Syngene, Frederick, MD).
Densitometry of the protein band corresponding to AMPD2 or ADSS was obtained using

52

ImageJ (National Institutes of Health, Bethesda, MD) and results were normalized to
that of wildtype.

Sample preparation for PNC enzyme activity assays: Wildtype mouse hearts
and HIF-1α Non-I, 2D, and 6D mouse hearts were perfused briefly with phosphate
buffer saline to wash out excess blood. Hearts were then ground into a fine powder
over liquid nitrogen and homogenized in a buffer consisting of 0.089M potassium
phosphate, 0.18M potassium chloride, and 0.1mM dithiothreitol with 1% v/v protease
inhibitor cocktail. BCA assay was used to determine the protein concentration of the
homogenates.
AMP deaminase activity: AMP deaminase enzyme activity was assessed using
a procedure described by Raffin (8). Homogenates were diluted to a protein
concentration of 2.5 µg/µl. 400 µl of the 2.5 µg/µl heart homogenate, which
corresponds to 1 mg of protein, were added to 2 ml of a reaction mixture containing
(mM): 50 cacodylic acid, 150 KCl, 10 AMP. A 250 µl aliquot of the reaction was taken
upon initiation of the reaction (t0) and after 2 hours of incubation at room temperature.
125 µl of 4% perchloric acid (Alfa Aesar, Ward Hill, MA) was used to extract nucleotides
from the reaction aliquots and IMP was detected at 254 nm using the high performance
liquid chromatography procedure described in chapter 2 and quantified using a
calibration curve. IMP production was obtained by subtracting the initial (t0) level from
that detected after 2 hours of incubation. AMP deaminase specific activity was reported
as nmoles of IMP produced per minute per mg protein.
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ADSS activity: Homogenates were diluted to a protein concentration of 2 µg/µl in
substrate free reaction buffer consisting of 27 mM imidazole-HCl, 50 mM potassium
chloride, 8.3 mM MgCl2, 5 mM KH2PO4, and 0.16 mM DTT (pH 7.2). 250 µl of the 2
µg/µl homogenate were added to 350 µl of substrate buffer (i.e. substrate free reaction
buffer plus substrate). The final concentration of substrates (mM) in 600 µl of reaction
volume was 0.5 IMP, 0.3 GTP, 16 creatine phosphate, 4 aspartate, and 0.25 mg
creatine phosphokinase. The ADSS reaction is powered by hydrolysis of GTP and the
resulting GDP strongly inhibits this reaction step in the PNC. As a result, the nucleotide
triphosphate regenerating system consisting of creatine phosphate and creatine
phosphokinase was added to the reaction to regenerate GTP. S-AMP levels, measured
by HPLC at 268 nm were determined upon initiation of the reaction (t0) and after 30
minutes (t30) of incubation at 37oC and quantified using a calibration curve. S-AMP
production was calculated by subtracting the initial (t0) S-AMP content from that found
after 30 minutes (t30) of reaction. Specific activity of ADSS was expressed as µmoles of
S-AMP produced per minute per mg protein.
ADSL activity: The protein concentration of heart homogenates was diluted to 2
µg/µl using 50 mM tris (pH 7.4). 250 µg (125 µl) of each sample were added to 175 µl
of reaction buffer (50 mM tris with 0.25 mM S-AMP). Immediately after the reaction was
started (t0), a 125 µl aliquot of sample was taken and nucleotides were extracted with
62.5 µl of 4% perchloric acid in order to get a basal level of AMP. The remaining
sample was allowed to react for 30 minutes (t30) at 37oC. After the 30 minute incubation
period, 125 µl of sample were drawn and nucleotide extraction was again extracted with
62.5 µl of 4% perchloric acid. Perchloric acid extracts were adjusted to pH 7 with a
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buffer consisting of 4/5 volume 2M KOH and 1/5 volume 1M KH2PO4. AMP in the
neutralized perchloric acid extracts was determined using reverse phase HPLC at 254
nm and quantified with its corresponding calibration curve. AMP production was
calculated by subtracting the initial (t0) AMP content from that detected after 30 minutes
(t30) of reaction incubation. ADSL activity is reported as µmoles of AMP generated per
minute per mg protein.

Statistical analysis: Data reported are expressed as means±SEM. Statistical
significance was tested using one-way ANOVA followed by SNK post-hoc test using
GraphPad Prism 5 (La Jolla, CA). Where appropriate, Student's t-test was used to test
for statistical significance.
RESULTS
Figure 3.3a shows that mRNA levels of the enzyme regulating entry into the
purine nucleotide cycle (PNC), AMP deaminase isoform 2 (AMPD2) is upregulated in
Non-I, 2D, and 6D mouse hearts as compared to wildtype. It took 6 days of HIF-1α
induction (6D) however, for AMPD2 protein to accumulate to levels greater than that
found in wildtype mouse hearts (Figures 3.3b & 3.3c). In concurrence with the elevated
protein expression of AMPD2 in the 6D mouse heart extracts, we find that activity of
AMP deaminase was increased relative to wildtype hearts (Figure 3.3d). We did not
observe any changes in protein or activity level of adenylosuccinate synthetase and
adenylosuccinate lyase between wildtype and HIF-1α expressing (6D) mouse hearts
(Figures 3.4 & 3.5).
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DISCUSSION

The purine nucleotide cycle has been shown to operate in skeletal muscle,
kidney, brain, liver and heart (1, 6, 7, 9, 11). Here, we find that the enzyme regulating
entry into the purine nucleotide cycle, AMP deaminase isoform 2 (AMPD2) is induced
by HIF-1α. During ischemia, glycolysis is used to generate ATP. However, the rate at
which ATP is produced from glycolysis cannot match the rate of ATP consumption.
Thus, ATP is depleted and AMP accumulates. AMP can be metabolized to IMP by
AMP deaminase. Metabolism of IMP by subsequent enzymes of the PNC regenerates
AMP, which can be thought of as a conservation mechanism for the heart's adenine
nucleotides. In addition to glycolysis, which supplies ATP, we now know that HIF-1α
induces AMPD2, the entry point to the PNC. These two pathways may function to
enhance the preservation of the heart's adenine nucleotide pool during ischemia.
Taken together, these results provide the rationale for us to perform a detailed
investigation on the effect that HIF-1α exerts on nucleotide metabolism in the ischemic
heart, results of which will be presented in the next chapter.
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FIGURES

Figure 3.1: Pathways leading to succinate production during anoxia in diving mammals as
proposed by Peter Hochachka. One pathway starts with the conversion of pyruvate to alanine,
which generates α-ketoglutarate. α-Ketoglutarate then enters the mitochondria and is converted
to succinyl-CoA. In a reaction catalyzed by succinate thiokinase, succinyl-CoA is converted to
succinate and GTP or ATP is concamittantly produced. An alternative pathway initiates when
aspartate becomes transaminated to oxaloacetate. Malate dehydrogenase then converts
oxaloacetate to malate, which enters the mitochondria where it is metabolized to fumarate.
Fumarate then becomes reduced to succinate at complex II. Adapted from Hochachka et al. (3)
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Figure 3.2: The purine nucleotide cycle (PNC). The PNC starts when AMP is deaminated to
IMP by AMP deaminase (AMPD). Subsequently, IMP is converted to S-AMP in a reaction
catalyzed by adenylosuccinate synthetase (ADSS). S-AMP is converted back to AMP utilizing
adenylosuccinate lyase (ADSL). The ADSL reaction step also produces fumarate, which can be
used as an alternative terminal electron acceptor in the electron transport chain to maintain
anaerobic mitochondrial respiration.
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Figure 3.3: HIF-1α upregulates the mRNA, protein, and activity of AMP deaminase (AMPD) in
mouse hearts. Hearts were obtained from wildtype mice and those in which the HIF-1α-PPN
transgene was suppressed (Non-I) or allowed to be expressed for 2 days (2D) or 6 days (6D).
a) AMPD2 gene expression in mouse heart homogenates was examined using qPCR and
normalized to reference gene transferrin. Results are expressed as the % change in gene
expression relative to WT (n=6). b) Western blot showing AMPD2 protein expression in mouse
heart homogenates. c) Quantification of AMPD2 protein levels in mouse heart homogenates
(n=6-8). d) AMPD activity assessed by the amount of IMP produced per minute per mg protein
in a buffer system containing excess AMP (n=5). * P<0.05 versus WT.

Figure 3.4: HIF-1α does not change the protein expression or activity of ADSS in the heart.
Extracts were obtained from wildtype (WT) mouse hearts and those where the HIF-1α-PPN
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transgene has been suppressed (Non-I), expressed for 2 days (2D), or expressed for 6 days
(6D) to examine protein and activity levels of ADSS. a) Representative western blot showing
ADSS expression in adult mouse heart extracts (top); average ADSS protein expression in
mouse hearts (n=3-5) (bottom). b) Average ADSS activity in mouse hearts (n=5).

Figure 3.5: Adenylosuccinate lyase (ADSL) activity is not different in wildtype and HIF-1α
expressing 6 day (6D) mouse hearts. Hearts were obtained from wildtype mice and those that
have been denied doxycycline to express the HIF-1α-PPN transgene for 6 days (6D) and
activity of adenylosuccinate lyase was examined. n=3.
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CHAPTER 4
HIF-1α IN THE HEART: REMODELING OF NUCLEOTIDE METABOLISM LEADING
TO ATTENUATION OF ADENOSINE ACCUMULATION DURING ISCHEMIC STRESS

SUMMARY
O2 delivery to heart tissue is compromised during ischemia. As a result, ATP production
via oxidative phosphorylation becomes inhibited. While glycolysis can produce ATP
anaerobically, the rate of ATP synthesis from this process cannot match the rate of ATP
consumption. Therefore, ischemia in the heart leads to a net depletion of ATP and the
nucleotide pool while nucleobases accumulate. Having identified that HIF-1α
upregulates AMP deaminase, the entry point to the adenylate conserving purine
nucleotide cycle (PNC), we sought to examine how HIF-1α influences nucleotide
metabolism in the ischemic heart. Here, we found that HIF-1α expression in the heart
prevents the degradation of nucleotides under the ischemic setting. As ATP degrades
during ischemia, AMP accumulates. AMP can be metabolized to adenosine by 5'nucleotidase isoform 1 or the PNC. Here, we noted that HIF-1α limits adenosine
accumulation in the ischemic heart, consistent with the shunting of AMP metabolism
towards the cardioprotective PNC. Our group previously showed that HIF-1α confers
ischemic tolerance by allowing cardiomyocytes to use PNC derived fumarate to sustain
anaerobic mitochondrial respiration. Upon further examination, we found that HIF-1α
also upregulates adenosine deaminase, an enzyme that degrades adenosine. HIF-1α's
role in reducing adenosine accumulation in the ischemic heart may seem paradoxical
since adenosine is known to be a cardioprotective molecule. However, recent evidence
indicates that chronic exposure to adenosine can cause toxicity. Therefore, HIF-1α
expression may allow the heart to circumvent the toxicity caused by chronic adenosine
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exposure. Collectively, we found that HIF-1α not only preserves the hearts adenine
nucleotide pool, but it also upregulates pathways whose role in cardioprotection may go
beyond the remodeling of nucleotide metabolism.

INTRODUCTION
During ischemia, ATP production via oxidative phosphorylation ceases.
Glycolysis can generate ATP anaerobically, however, the rate of ATP synthesis from
glycolysis cannot match the rate at which ATP is consumed. ATP and the heart's
nucleotide pool becomes rapidly depleted during ischemia (Figure 4.1) (1, 15, 16, 34).
This results in the formation of non-phosphorylated nucleoside products such as inosine
and adenosine, which can freely diffuse into the extracellular space, where they are
further degraded to nucleobases such as hypoxanthine (Figure 4.1). The loss of
nucleosides and nucleobases to the extracellular space reduces the amount of
precursors that are available for re-synthesis of purine nucleotides via the salvage
pathway. Thus, this represents a critical route in which the cellular nucleotide pool is
depleted during ischemic insult.

Maintenance of the adenine nucleotide pool is of great importance in the
ischemic heart, as these are the metabolites necessary for ATP production. The
synthesis of adenine nucleotides from de novo pathways is very slow and energetically
expensive (25) and the loss of precursors limits nucleotide resynthesis from salvage
pathways. Furthermore, de novo nucleotide synthesis requires glucose-6-phosphate,
an intermediate in glycolysis (see review by Lunt et al, 2011) (20). Under the ischemic
setting, not only is oxygen delivery diminished, but compromised blood flow in the
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coronary vasculature limits the delivery of nutrients such as glucose, which is
metabolized by glycolysis to generate glucose-6-phosphate. As such, the diminished
glucose delivery to the heart tissue further hinders de novo nucleotide synthesis. While
contractile activity is abolished upon the onset of ischemia, the heart still relies on ATP
to maintain ionic homeostasis. Hence, mechanisms that help conserve the heart's
valuable nucleotide resources could prove protective.

In the previous chapter, we show that the reaction step regulating entry into the
purine nucleotide cycle (PNC), AMP deaminase isoform 2 (AMPD2) is induced by HIF1α. Activity of the PNC has been demonstrated in isolated cardiomyocytes subjected to
anoxic stress (13, 14, 33). Sabina et al. proposed that the PNC acts to conserve the
cellular adenine nucleotide pool (32). As ATP is degraded during ischemia, AMP
accumulates. The fate of AMP is either metabolism to adenosine by 5'-nucleotidase
isoform 1 (5'NT-I) or IMP by AMPD2 (Figure 4.1). Adenosine is uncharged and freely
diffuses out of the myocyte. Alternatively, the IMP that is generated by AMP deaminase
can be utilized by subsequent steps of the PNC to regenerate AMP, thus fulfilling the
PNC's role in adenine nucleotide conservation. In addition to glycolysis, we have
identified another HIF-1α induced pathway that may exert protective effects on the
heart's nucleotide resources during ischemia. As such, it became important for us to
examine in detail, the effects that HIF-1α exerts on nucleotide metabolism in the heart
during ischemic stress.
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EXPERIMENTAL PROCEDURES
Nucleotide metabolism: Nucleotide metabolism during ischemia was examined
in WT as well as HIF-1α Non-I, 2D, and 6D mouse hearts. All hearts were perfused with
Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8
NaHCO3, 2.5 CaCl2, and 10.6 glucose on the Langendorff apparatus for 25 minutes to
allow stabilization. Following the stabilization period, hearts were subjected to either 5,
10, 20, or 30 minutes of ischemia, or perfusion for 2.5 minutes with glucose-free Krebs
buffer containing 5 mM glycolytic inhibitor iodoacetate (Acros Organics, Morris Plains,
NJ) followed by 20 minutes of ischemia. After ischemic stress, nucleotides were
extracted with 400 µl of 4% perchloric acid and were measured with HPLC as detailed
in chapter 2. Nucleotides were quantified using their respective calibration curve and
results were expressed as µmoles of nucleotide per gram dry tissue.

Protein expression of adenosine deaminase: Protein samples from mouse
hearts were prepared according to experimental procedures outlined in chapter 2.
Adenosine deaminase was probed using a rabbit polyclonal antibody diluted 1:400 in
TBS-T (Novus Biologicals, Littleton,CO) and incubated overnight with rocking at 4oC.
After incubation in primary antibody, the membranes were washed 5x5 minutes with
TBS-T and then incubated with a goat anti-rabbit horseradish peroxidase conjugated
secondary antibody (EMD) for 1 hour at room temperature. The band corresponding to
adenosine deaminase was detected using the Pierce supersignal chemiluminescence
substrate in the G:BOX imaging system (Syngene, Frederick, MD). Densitometry of the
protein band corresponding to adenosine deaminase was done using ImageJ (National
Institutes of Health, Bethesda, MD) and results were normalized to that of wildtype.
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Adenosine deaminase activity: Activity of adenosine deaminase was
determined in WT and 6D mouse heart homogenates according to a method developed
by Hartwick et al (11). The volume of homogenate corresponding to 250 µg protein was
added to a reaction mixture containing 0.065F KH2PO4, 0.06F Na2HPO4, and 17.5 mM
adenosine. The volume of reaction mixture added to the homogenates was such that
the final adenosine concentration in the reaction was 3.5 mM. Half of the reaction was
immediately taken out to obtain the initial inosine content (t0). The remaining half of the
reaction was allowed to incubate at room temperature for 40 minutes. HPLC was used
to monitor the amount of product (i.e. inosine) formed during the reaction. The amount
of inosine produced during the incubation period is obtained by subtracting the inosine
content at the start of the reaction (t0) from the inosine content after the 40 minute
incubation period. Adenosine deaminase specific activity was expressed as nmoles of
inosine formed per minute per mg protein.

Statistical analysis: Data reported are expressed as means±SEM. Statistical
significance was tested using one-way ANOVA followed by SNK post-hoc test using
GraphPad Prism 5 (La Jolla, CA). Where appropriate, Student's t-test was used to test
for statistical significance.

RESULTS
Figure 4.2 shows that HIF-1α allows for better preservation of the heart's total
adenine nucleotide pool (i.e. sum of ATP, ADP, and AMP) during ischemic stress.
As ATP degrades during ischemia, AMP accumulates. AMP accumulation was
hastened in wildtype mouse hearts during ischemia (Figure 4.3). The accumulation of
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AMP during ischemia was delayed in the HIF-1α-PPN mouse hearts. It took 20 minutes
of ischemic stress for AMP in Non-I and 2D hearts to reach levels equivalent to wildtype
(Figure 4.3). After 30 minutes of ischemia, AMP accumulation was equal across the
heart groups (Figure 4.3).

AMP that accumulates during ischemia has two fates. First, AMP can be
degraded to adenosine via a reaction catalyzed by 5'-nucleotidase (Figure 4.1). As
evident by Figure 4.4a, adenosine accumulated readily in wildtype hearts upon
exposure to ischemic insult. On the other hand, adenosine accumulation in Non-I and
2D hearts was delayed and did not match the levels found in wildtype until 30 minutes
of ischemia have elapsed. In hearts that have been expressing HIF-1α for 6 days,
adenosine levels failed to increase even after 30 minutes of ischemia (Figure 4.4a).
Alternatively, AMP can be metabolized to IMP during ischemia. The Non-I, 2D, and 6D
heart accumulated lower levels of IMP as compared to wildtype after 20 and 30 minutes
of ischemia (Figure 4.4b).

Figure 4.5a shows that inosine levels during the initial 20 minutes of ischemia
was lower in 6D hearts as compared to wildtype, Non-I, and 2D hearts. Nucleoside
phosphorylase can further metabolize inosine to hypoxanthine, which is further
degraded to xanthine. Here, we found that while hypoxanthine and xanthine levels
increased in the ischemic heart, they were not different in HIF-1α-PPN hearts as
compared to wildtype at any time point of ischemia (Figures 4.5b & 4.5c).

In this initial series of studies, we found that expression of HIF-1α for 6 days
prevented the buildup of adenosine in the ischemic heart. In chapter 2, we showed that
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HIF-1α expression for 6 days enhances glycolytic activity and preservation of ATP in the
heart during ischemia. Here, we also showed that in hearts where HIF-1α has been
expressed for 6 days, the accumulation of AMP was lower during the initial 20 minutes
of ischemia (Figure 4.3). Thus, the reduction of adenosine accumulation in HIF-1α
expressing hearts may merely reflect the lower amount of AMP available for metabolism
by 5'-nucleotidase.

To test our hypothesis, we perfused hearts with 5 mM of glycolytic inhibitor
iodoacetate followed by 20 minutes of ischemia. At the end of this ischemic stress
protocol, ATP, ADP, and AMP were reduced to similar levels in wildtype and 6D hearts
(Figure 4.6). Yet, 6D hearts still failed to accumulate adenosine to levels similar to that
in wildtype, while IMP level was not different between these two heart groups (Figure
4.7). Here, it is crucial to note that inosine, hypoxanthine, and xanthine accumulated to
higher levels in 6D mouse hearts as compared to wildtype after this ischemic stress
protocol (Figure 4.7). Taken together, our results indicate that pathways besides
glycolysis must be responsible for decreasing the accumulation of adenosine in the
ischemic 6D hearts.

An obvious explanation for the attenuation of adenosine in 6D hearts is the
increased expression of AMP deaminase isoform 2 (AMPD2). However, we also
considered the following two factors in our endeavor to identify mechanisms that
attenuated adenosine levels in the ischemic 6D HIF-1α expressing hearts. First is the
observation that less adenine nucleotides were degraded in the 6D hearts during the
ischemic time course but levels of hypoxanthine and xanthine that accumulated was
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equivalent to wildtype. Second, ATP, ADP, and AMP were depleted to the same level
in wildtype and 6D hearts when glycolysis was blocked prior to ischemia but yet 6D
hearts were able to accumulate more inosine, hypoxanthine, and xanthine, the
downstream degradation products of adenosine and IMP (Figure 4.1). These two
observations led us to believe that adenosine deaminase was upregulated in 6D hearts,
thus allowing for more rapid degradation of adenosine (Figure 4.1). Figure 4.8 shows
that indeed, protein and activity of adenosine deaminase is induced in the extracts of 6
day HIF-1α expressing hearts.

DISCUSSION
In these studies, we find that HIF-1α preserves adenine nucleotides during
ischemia in the heart. The accumulation of nucleotide breakdown products required the
shortest duration of ischemic stress in wildtype mouse hearts. A delay is observed in
Non-I and 2D hearts. The breakdown of adenine nucleotides is slowest in the 6D
hearts. These results suggests a pseuo-dose response such that nucleotide depletion
during ischemia is fastest in wildtype, slower in Non-I and 2D hearts, and slowest in 6D
hearts.

Studies where we blocked glycolysis prior to ischemia indicated additional
mechanisms contribute to the reduction of adenosine accumulation that we have
observed during ischemia in 6 day HIF-1α expressing hearts. The first mechanism we
considered was the reaction catalyzed by adenosine kinase, which converts adenosine
back to AMP. However, as ATP is needed as a phosphate donor to adenosine, the
likelihood that adenosine kinase is functional under ischemic conditions is slim. Indeed,
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it has been shown that adenosine kinase activity is suppressed during ischemic stress
(5, 21, 27).

Our finding that HIF-1α induces the expression of AMP deaminase isoform 2
(AMPD2) provides one explanation to our observation that HIF-1α expression reduces
adenosine accumulation in ischemic heart. This suggests that AMP metabolism is
diverted towards the PNC during ischemia in hearts that express HIF-1α, which should
enhance the production of fumarate. As our group has shown in the past, HIF-1α allows
cardiomyocytes to utilize fumarate derived from the PNC to maintain anaerobic
mitochondrial respiration, thus leading to enhanced ischemic tolerance. Our
observation that adenosine accumulation is limited in HIF-1α expressing hearts is
consistent with the higher activity of the cardioprotective PNC. Surprisingly, we
observed that in HIF-1α expressing hearts, IMP did not accumulate to levels higher than
wildtype hearts during ischemia, even though HIF-1α upregulates AMP deaminase.
Unlike tetanic activity of skeletal muscle, where IMP accumulation is proportional to the
amount of ATP degraded (26), IMP has not been detected in ischemic hearts (16). This
has led Manfredi to propose that unknown mechanisms are preventing IMP
accumulation in the heart during ischemia (24). Taken together, a multitude of factors
may play a role in determing the levels of IMP in the heart during ischemic stress and
we hope to identify these in future studies.

To further identify pathways that contribute to reduced adenosine accumulation
during ischemia, we focused on our observation that 6D HIF-1α expressing hearts were
able to achieve equal or higher levels of adenosine breakdown products during
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ischemia as compared to wildtype mouse hearts. Consistent with this result, we found
that adenosine deaminase protein and activity in heart extracts from 6D mice were
higher than wildtype. Our results are consistent with work done by Eltzschig, which
showed that hypoxia induces the mRNA and protein expression of adenosine
deaminase (7).

The finding that HIF-1α limits adenosine accumulation contradicts the protective
role that this metabolite has been ascribed, particularly in the realm of cardioprotection
(17, 29, 35, 37). This is achieved through signaling via various isoforms of cell surface
adenosine receptors (6, 19, 28). Immune response has been recognized to contribute
to the adverse effects associated with ischemia (10, 18). Various studies show that
adenosine plays a role in suppressing immune cells by inhibiting their transmigration
through the vasculature and reducing their production of proinflammatory cytokines (3,
9, 12). On the other hand, it has been recognized that chronic exposure to adenosine
causes toxicity. Blackburn has postulated that toxicity from chronic adenosine exposure
may arise from receptor downregulation and activation of adenosine receptors on
surrounding immune cells (2). Downey's group showed that prolong exposure of
adenosine receptors to agonist led to abolishment of cardioprotection provided by
preconditioning (36). These results are suggestive of receptor downregulation as a
result of chronic adenosine exposure. Adenosine has been shown to stimulate mast
cell degranulation (31). In addition, adenosine may also be proarrhythmic (8, 23).
Furthermore, adenosine has been shown to induce fibrosis (4, 22, 30). Thus, HIF-1α
may play a role in maintaining the intricate balance between the benefits of adenosine
signaling and ill-effects associated with chronic adenosine exposure. Future studies
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should examine whether adenosine exposure, long-term, triggers maladaptive
responses during ischemia and whether HIF-1α provides an approach to limit this.

Collectively, nucleotide metabolism is remodeled by HIF-1α. These remodeling
processes result in better preservation of adenine nucleotides during ischemia. More
importantly, HIF-1α reduces the amount of adenosine that accumulates in the ischemic
heart. This result is consistent with higher activity of the cardioprotective PNC pathway
and also suggests that HIF-1α expression in the heart may limit the toxicity associated
with chronic exposure to adenosine.
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FIGURES

Figure 4.1: Nucleotide degradation pathways in the ischemic heart. During ischemia, the rate
of ATP consumption exceeds its synthesis from glycolysis. As a result, there is a net
degradation of ATP and the heart's nucleotide pool while the nucleobase hypoxanthine
accumulates. PNC = purine nucleotide cycle. AMPD2 = AMP deaminase isoform 2. ADSS =
adenylosuccinate synthetase. ADSL = adenylosuccinate lyase. 5'NT-1 = 5'-nucleotidase
isoform 1 (AMP specific). 5'NT-II = 5'-nucleotidase isoform 2 (IMP specific). HPRT =
hypoxanthine phosphoribosyl transferase. HIF induced pathways are denoted by blue arrows.
Major pathways that have been proposed previously by others are shown in bold black arrows.
Adapted from Jennings et al. (16).
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Figure 4.2: Wildtype mouse hearts are inept at preserving the adenine nucleotide pool during
ischemia. Wildtype mouse hearts, hearts not expressing the HIF-1α-PPN transgene (Non-I),
and hearts made to express the HIF-1α-PPN transgene for 2 days (2D) and 6 days (6D) were
subjected to the indicated durations of ischemia. Nucleotides were measured using HPLC and
the sum of ATP, ADP, and AMP was taken as the total adenine nucleotide pool. Pre-isch
denotes pre-ischemia. * P<0.05 versus wildtype. # P<0.05 versus 6D. n=3-9.

Figure 4.3: AMP levels in ischemic adult mouse hearts. Hearts were obtained from wildtype
mice and those in which the HIF-1α-PPN transgene is suppressed (Non-I), expressed for 2 days
(2D) or 6 days (6D). AMP levels were measured at the indicated durations of ischemic stress.
Pre-isch denotes pre-ischemia. * P<0.05 versus wildtype. # P<0.05 versus 6D. n=3-9.

Figure 4.4: HIF-1α reduces the amount of adenosine and IMP that accumulates in the ischemic
heart. Wildtype mouse hearts as well as those not expressing the HIF-1α-PPN transgene (NonI), expressing the HIF-1α-PPN transgene for 2 days (2D) and 6 days (6D) were subjected to the
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indicated durations of ischemia and nucleotides were measured with HPLC. a) Adenosine. b)
IMP. * P<0.05 versus wildtype. # P<0.05 versus 6D. n=3-9.

Figure 4.5: Accumulation of inosine, hypoxanthine, and xanthine in mouse hearts subjected to
total ex vivo ischemic stress. Hearts were obtained from wildtype mice and those in which the
HIF-1α-PPN transgene is suppressed (Non-I), expressed for 2 days (2D) or 6 days (6D). Hearts
were subjected to the indicated durations of ischemia. Nucleotides were extracted and
measured using HPLC. Pre-isch denotes pre-ischemia. a) Inosine. b) Hypoxanthine. c)
Xanthine. * P<0.05 versus wildtype, # P<0.05 versus 6D. n=3-9.

Figure 4.6: Inhibition of glycolysis reduces post-ischemic content of ATP, ADP, and AMP to
similar levels in wildtype hearts and those expressing the HIF-1α-PPN transgene for 6 days.
Hearts were obtained from wildtype mice and those in which the HIF-1α-PPN transgene was
expressed for 6 days (6D). Hearts were perfused for 2.5 minutes with 5 mM glycolytic inhibitor
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iodoacetate then subjected to 20 minutes of ex vivo ischemia. After ischemic stress,
nucleotides were extracted and measured using HPLC. n=4-5.

Figure 4.7: Inhibition of glycolysis followed by ischemia leads to attenuation of adenosine (Ado)
accumulation but increases in accumulation of inosine (Ino), hypoxanthine (HX), and xanthine
(Xan) in hearts expressing the HIF-1α-PPN transgene. Hearts were obtained from wildtype
mice and those in which the HIF-1α-PPN transgene was expressed for 6 days (6D). Hearts
were perfused for 2.5 minutes with 5 mM glycolytic inhibitor iodoacetate then subjected to 20
minutes of ex vivo ischemia. After ischemic stress, nucleotides were extracted and measured
using HPLC. * P<0.05 versus wildtype. n=4-5.

Figure 4.8: HIF-1α expression induces the protein and activity of adenosine deaminase (ADA).
Heart homogenates were obtained from wildtype mice and those in which the HIF-1α-PPN
transgene was suppressed (Non-I), expressed for 2 days (2D), or expressed for 6 days (6D). a)
Representative Western Blot showing adenosine deaminase expression (top); average
expression of adenosine deaminase from 4 to 7 mouse hearts (bottom). b) Adenosine
deaminase specific activity in homogenates from 5 mouse hearts. # P<0.05 versus 6D. *
P<0.05 versus wildtype.
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CHAPTER 5
THE PURINE NUCLEOTIDE CYCLE AND ITS EFFECTS ON NUCLEOTIDE
METABOLISM IN THE ISCHEMIC HEART

SUMMARY
We found that HIF-1α reduces the accumulation of adenosine in the ischemic heart.
This is consistent with the shunting of AMP metabolism towards AMP deaminase, which
is upregulated by HIF-1α. AMP deaminase represents the step regulating entry into the
nucleotide metabolic pathway known as the purine nucleotide cycle (PNC). To
establish a better understanding of the role that the PNC plays in the ischemic heart, we
perfused wildtype and 6 day HIF-1α induced (6D) mouse hearts with 50 µg/ml (0.42
mM) adenylosuccinate synthetase inhibitor, hadacidin followed by treatment of hearts to
30 minutes of ex vivo ischemic stress. We found that inhibition of the PNC led to a
reduction of ATP, ATP:ADP, and adenylate energy charge in wildtype and 6D hearts
during ischemia. The inhibition of adenylosuccinate synthetase by hadacidin should
decrease the availability of fumarate used to maintain anaerobic mitochondrial
respiration. Our studies allow us to propose a new physiological role for the PNC,
which is that the PNC preserves ATP, ATP:ADP, and adenylate energy charge via the
provision of fumarate, which is used as an alternative terminal electron acceptor in
place of O2 to maintain mitochondrial polarization during ischemia. This prevents the
reverse mode operation of the F0F1 ATP synthase, which consumes ATP in order to
maintain the mitochondrial membrane potential during ischemia. Therefore, the
induction of the PNC may contribute to the better preservation of energy charge up to
20 minutes of ischemic stress that we have observed in 6D HIF-1α expressing hearts.
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INTRODUCTION
In chapter 2, we showed that HIF-1α upregulates AMP deaminase, the enzyme
regulating entry into the PNC. Furthermore, our finding that HIF-1α attenuates
adenosine accumulation in ischemic hearts is consistent with the induction of AMP
deaminase. Studies related to the PNC have for the most part been done on skeletal
muscle. On the other hand, knowledge regarding the PNC and its function in the heart
remains much more elusive. Unlike skeletal muscle, studies by Taegtmeyer found that
workload does not affect the activity of the PNC in heart (8). This led the group to
discount any significant role for the PNC in the heart. However, the heart is particularly
well equipped to maintain its high energy phosphate content as workload is varied (5).
Therefore, the model system used by Taegtmeyer may not have been able to capture
the physiological significance of the PNC in the heart (8). To delineate the role of the
PNC in the heart, we subjected hearts to ex vivo ischemia, a condition similar to
exercise in skeletal muscle where ATP becomes readily depleted. Hearts were
subjected to 30 minutes of ischemia alone or pre-treatment with hadacidin, which is a
PNC inhibitor at the step of adenylosuccinate synthetase, followed by exposure to 30
minutes of ischemic stress. Nucleotide content in the heart was measured after
ischemic stress. Results were compared between wildtype and HIF-1α expressing
mouse hearts.

EXPERIMENTAL PROCEDURES
Nucleotide metabolism: Wildtype mouse hearts and hearts derived from our HIF1α-PPN non-induced (Non-I), 2 day induced (2D), and 6 day induced (6D) mice were
perfused with Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2
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KH2PO4, 24.8 NaHCO3, 2.5 CaCl2, and 10.6 glucose on the Langendorff apparatus for
25 minutes to allow stabilization. Following the stabilization period, hearts were either
subjected to 5, 10, 20, or 30 minutes of ischemia or perfused for 15 minutes with Krebs
buffer containing 50 µg/ml hadacidin followed by 30 minutes of ischemia. Hearts were
freeze clamped and nucleotides were extracted with 400 µl of 4% perchloric acid. The
nucleotide extracts were incubated on ice for 20 minutes. Following incubation, the
nucleotide extracts were centrifuged at 15,000 g for 15 minutes at 4°C and the
supernatant containing nucleotides was removed. The remaining pellet was lyophilized
in order to obtain the dry weight (grams) of tissue collected. Nucleotides were
measured with HPLC and quantified with their respective calibration curve. Results are
expressed as µmoles of nucleotide per gram dry tissue.

Energy status of the heart: The heart's energy status provides an indication of
the energy that can be harnessed during ATP hydrolysis that can be used to carry out
cellular work and is commonly assessed by calculating the ATP:ADP ratio. The higher
the ATP:ADP ratio, the more energy is harnessed upon removal of a phosphate group
from ATP. However, under conditions when cellular energetics is compromised, AMP
content is much more easily perturbed compared to the content of ADP (3). For
example, AMP:ATP is equal to (ADP:ATP)2 (3). Thus, a 5 fold increase in ADP:ATP
leads to a 25 fold amplification in AMP:ATP. Therefore, AMP is the best suited
metabolite used to regulate cellular energetics. In fact, the cell utilizes AMP activated
protein kinase as a regulator of cellular energetics via modulation of various metabolic
pathways (4). Thus, AMP content must be accounted for when quantifying the energy
status of the cell. The adenylate energy charge (EC), first proposed by Atkinson (1), is
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calculated from the values of the adenine nucleotide pool and is given by Equation 1.
This parameter is starting to be much more commonly used to describe cellular
energetics. EC ranges from 0 to 1 and is approximately 0.8 in a healthy cell. A higher
EC indicates that ATP utilization is favored.
energy charge 

ATP+0.5ADP
ATP+ADP+AMP

Equation 1

Statistical analysis: Data reported here are expressed as means±SEM.
Statistical significance was tested using one way ANOVA with SNK post-hoc test or
Student's t-test in GraphPad Prism 5 (La Jolla, CA).

RESULTS
In these studies, we observed that HIF-1α induction for 6 days (6D) provides
strong preservation of ATP:ADP (Figure 2.5) and adenylate energy charge (Figure 5.1).
We find that hadacidin treatment prior to ischemia led to a drastic reduction in ATP and
ADP in both wildtype and 6D mouse hearts (Figure 5.2a and 5.2b). AMP levels
increased in both wildtype and 6D hearts when hadacidin was administered prior to 30
minutes of ischemia (Figure 5.2c). The changes in adenine nucleotide content resulted
in a substantial decrease in the heart's ATP:ADP and adenylate energy charge (Figure
5.3).

Next, we examined the effect that hadacidin had on nucleotide breakdown
products adenosine and IMP in the ischemic heart. While adenosine levels did not
change in 6D hearts, it more than doubled in hearts from wildtype mice (Figure 5.4a).
We find that hadacidin had no effect on IMP content in wildtype hearts and 6D hearts
that were subjected to 30 minutes of ex vivo ischemia (Figure 5.4b). Adenosine and
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IMP can both be degraded to inosine, which is then metabolized by nucleoside
phosphorylase to hypoxanthine. We noted that levels of these metabolites were
unaltered when hadacidin was administered prior to the initiation of ischemic stress
(Figure 5.5).

DISCUSSION
The purine nucleotide cycle has been postulated to play a role in conserving
adenine nucleotides. For instance, AMP deaminase deficiency leads to exercise fatigue
and poor recovery of the skeletal muscle's adenine nucleotide pool upon termination of
intense physical activity (6). Here, we find that inhibiting the PNC with hadacidin prior to
ischemia did not enhance the decline of the heart's total adenine nucleotide pool or alter
the accumulation of nucleotide degradation products. Only changes in the distribution
of adenine nucleotides were observed, which is reflected as a decrease in ATP,
ATP:ADP, and adenylate energy charge. The lowering of energy charge under these
stress conditions severely limits the heart's ability to perform cellular work.

The preservation of cellular energy status (i.e. ATP:ADP ratio) is one of the
previously postulated roles that the PNC plays. This is brought about by the coupling of
the adenylate kinase (2 ADP ↔ ATP + AMP) and the AMP deaminase reactions,
whereby metabolism of AMP by AMP deaminase shifts the equilibrium of adenylate
kinase towards ATP synthesis, thus preserving the ATP:ADP ratio. Data obtained from
this study allows us to propose a novel approach in which the PNC preserves energy
status. While fumarate reduction at complex II can support ATP production by the ATP
synthase, it has been argued persuasively that this mechanism is unlikely to occur both
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on theoretical and experimental grounds (2). Inhibition of adenylosuccinate synthetase
by hadacidin should reduce the fumarate available for maintenance of anaerobic
mitochondrial respiration. As such, the F0F1 ATP synthase would act in reverse in order
to maintain the mitochondrial membrane potential, in the process further depleting ATP.
Therefore, reducing the heart's ATP, ATP:ADP, and energy charge during ischemic
stress. Thus, our novel proposal is that activity of the PNC prevents the reversal of the
F0F1 ATP synthase in order to maintain the mitochondrial membrane potential, thereby
preserving the heart's ATP during ischemic stress. Collectively, we have identified that
in addition to glycolysis, the PNC is another crucial mechanism that helps maintain the
heart's adenylate energy charge during ischemia. The induction of the PNC by HIF-1α
may contribute to the ability of the HIF-1α expressing (6D) hearts to preserve energy
charge better than wildtype hearts, at least up to 20 minutes of ischemic stress.
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FIGURES

Figure 5.1: HIF-1α preserves adenylate energy charge during ischemia. Hearts from wildtype
mice and those maintained on doxycycline to suppress the HIF-1α-PPN transgene (Non-I),
denied doxycycline for 2 days (2D) or 6 days (6D) to express the HIF-1α-PPN transgene for 2
and 6 days, respectively, were subjected to the indicated durations of ex vivo ischemia and
nucleotides ATP, ADP, and AMP were measured using HPLC and adenylate energy charge
was calculated. Pre-isch = pre-ischemia. * denotes P<0.05 versus wildtype. # denotes P<0.05
versus 6D. n=3-9.

Figure 5.2: Hadacidin treatment prior to ischemic stress further reduces ATP and ADP but
increases AMP accumulation in the heart. Hearts were obtained from wildtype mice and those
denied doxycycline for 6 days (6D) to induce the expression of the HIF-1α-PPN transgene.
Hearts were subjected to 30 minutes of ex vivo ischemia with or without prior treatment with
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PNC inhibitor, hadacidin. After ischemia, nucleotides were extracted from the hearts and
measured using HPLC. a) ATP. b) ADP. c) AMP. * P<0.05 versus wildtype of the similar
treatment group. § P<0.05 versus hearts without hadacidin treatment. n=5. Note that data
from hearts subjected to 30 minutes of ischemia alone were taken from the ischemic time
course studies presented in chapter 4.

Figure 5.3: Inhibition of ADSS with hadacidin prior to ischemia drastically decreases the heart's
ATP:ADP and energy charge during ischemia. Wildtype and 6D mouse hearts were subjected
to 30 minutes of ex vivo ischemia with or without prior treatment with PNC inhibitor, hadacidin.
a) ATP:ADP ratio. b) Energy charge. § P<0.05 versus hearts without hadacidin treatment.
n=5. Note that data from hearts subjected to 30 minutes of ischemia alone were taken from the
ischemic time course studies presented in chapter 4.

Figure 5.4: Effects of hadacidin treatment on adenosine and IMP accumulation in ischemic
mouse hearts. Hearts were obtained from wildtype mice as well as those denied doxycycline for
6 days (6D) to induce the expression of the HIF-1α-PPN transgene. Hearts were subjected to
30 minutes of ex vivo ischemia with or without prior treatment with PNC inhibitor, hadacidin.
After ischemia, nucleotides were extracted from the hearts and measured using HPLC. a)
Adenosine. b) IMP. * P<0.05 versus wildtype of similar treatment. § P<0.05 versus hearts
without hadacidin treatment. n=5. Data from hearts subjected to 30 minutes of ischemia alone
were taken from the ischemic time course studies presented in chapter 4.
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Figure 5.5: Hadacidin treatment prior to ischemia did not alter inosine or hypoxanthine content
in mouse hearts. Hearts were obtained from wildtype mice and those denied doxycycline for 6
days (6D) to allow expression of the HIF-1α-PPN transgene. Hearts were subjected to 30
minutes of ex vivo ischemia with or without prior treatment with PNC inhibitor, hadacidin. After
ischemia, nucleotides were extracted from the hearts and measured using HPLC. a) Inosine.
b) Hypoxanthine. * P<0.05 versus wildtype of similar treatment. n=5. Data from hearts
subjected to 30 minutes of ischemia alone were taken from the ischemic time course studies
presented in chapter 4.
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CHAPTER 6
HIF-1α IN THE HEART: UPREGULATION OF PURINE SALVAGE ENZYME
HYPOXANTHINE PHOSPHORIBOSYL TRANSFERASE (HPRT)
SUMMARY
Ischemia in the heart leads to rapid depletion of the adenine nucleotide pool as well as
accumulation of nucleotide degradation products such as hypoxanthine. Hypoxanthine
can be utilized by the salvage enzyme, hypoxanthine phosphoribosyl transferase
(HPRT) to resynthesize adenine nucleotides. Here we report that HPRT mRNA and
protein are induced by hypoxia inducible factor 1α (HIF-1α) in mouse hearts. We have
demonstrated that HIF-1α expression leads to increased hypoxanthine accumulation in
the ischemic heart. Thus, suggesting that HIF-1α expression provides hearts with a
higher capacity to regenerate adenine nucleotides upon recovery from ischemic stress.
On the other hand, hypoxanthine can be metabolized by xanthine oxidase upon
reperfusion to xanthine. This reaction concomitantly generates a burst of reactive
oxygen species (ROS). As a result, the induction of HPRT by HIF-1α may serve the
dual purpose of re-incorporating hypoxanthine back into the nucleotide pool and
preventing the production of harmful ROS in ischemia-reperfusion.
INTRODUCTION
During ischemia, the heart's adenine nucleotide pool is readily depleted and
nucleobases such as hypoxanthine accumulates (2–4). Hypoxanthine phosphoribosyl
transferase (HPRT) is an enzyme that plays a role in nucleotide salvage (Figure 6.1).
This enzyme catalyzes the transfer of the 5-phosphoribosyl group on phosphoribosyl
pyrophosphate (PRPP) to hypoxanthine, leading to resynthesis of IMP.
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Adenylosuccinate synthetase (ADSS), an enzyme of the purine nucleotide cycle (PNC)
can utilize IMP to generate AMP, which replenishes the heart's adenine nucleotides.
Hypoxanthine can also be degraded to xanthine by xanthine oxidase during reperfusion
when O2 is reintroduced to the tissue (Figure 6.1). The reaction catalyzed by xanthine
oxidase concomitantly generates a burst of reactive oxygen species in the form of H2O2.
Here, we wanted to determine whether HPRT, an enzyme that can stimulate nucleotide
resynthesis and compete with xanthine oxidase for hypoxanthine to potentially reduce
ROS is a HIF-1α induced cardioprotective pathway.

EXPERIMENTAL PROCEDURES
mRNA expression of HPRT: The mRNA expression of HPRT in wildtype and
HIF-1α Non-I, 2D, and 6D mouse hearts was examined using quantitative PCR. RNA
extraction and cDNA synthesis was described under experimental procedures in
chapter 3. Quantitative PCR was performed in triplicate for all samples in a 96 well
plate format on a CFX96 real-time PCR detection system (BioRad Laboratories,
Richmond, CA). 40 cycles were carried out. Each reaction consisted of 50 ng cDNA
and 1.5 µl of Quantitect HPRT or transferrin primer from Qiagen in 1x SsoFast
Evagreen supermix (BioRad Laboratories). HPRT mRNA expression was normalized to
that of reference gene transferrin and results were reported as a percent change in
gene expression relative to WT.

Protein expression of HPRT: Hearts were obtained from WT, Non-I, 2D, and 6D
mice. Protein sample was prepared according to experimental procedures stated in
chapter 2. HPRT was probed using a rabbit polyclonal primary antibody diluted to 1
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µg/ml in TBS-T (Novus Biologicals, Littleton, CO). The membranes were incubated at
4°C overnight. After incubation in primary antibody, the membranes were washed for 5
minutes in TBS-T (5x) before incubation with 1:2500 goat anti-rabbit HRP conjugated
secondary antibody (EMD Millipore, Billerica, MA). Protein bands were detected using
the Pierce supersignal chemiluminescence substrate (Thermoscientific) in the G:Box
imaging system (Syngene, Frederick, MD). Densitometry of the protein band
corresponding to HPRT was obtained using ImageJ (National Institutes of Health,
Bethesda, MD) and results were normalized to that of WT.

Statistical analysis: Data are expressed as means±SEM. One-way ANOVA was
performed followed by SNK post-hoc test using GraphPad Prism 5 (La Jolla, CA).

RESULTS
Figure 6.2a shows that HIF-1α induces the mRNA of HPRT. In concurrence with
the mRNA levels, we show that HIF-1α also induces the protein expression of HPRT
(Figure 6.2b).

DISCUSSION
Here we report that HIF-1α induces the mRNA and protein of nucleotide salvage
enzyme hypoxanthine phosphoribosyl transferase (HPRT). We noted in chapter 4 that
HIF-1α expression enhances the accumulation of hypoxanthine during ischemia.
Hypoxanthine can either be a good or harmful metabolite. It can be utilized by HPRT to
resynthesize adenine nucleotides. However, it can also be converted by xanthine
oxidase to xanthine when oxygen is reintroduced during reperfusion. The metabolism
of hypoxanthine by xanthine oxidase leads to a burst of ROS production. It has been
94

demonstrated that oxypurinol, a xanthine oxidase inhibitor reduces ROS and improves
cardiac function after ischemia-reperfusion stress (5). Thus, the induction of HPRT by
HIF-1α may divert hypoxanthine away from xanthine oxidase metabolism, leading to
attenuation of ROS. Taken together, the induction of HPRT by HIF-1α may enhance
the re-assimilation hypoxanthine back into the adenine nucleotide pool and prevent
production of harmful ROS during ischemia-reperfusion.
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FIGURES

Figure 6.1: Hypoxanthine phosphoribosyl transferase (HPRT) reaction mechanism. HPRT
catalyzes the transfer of the 5-phosphoribosyl group on phosphoribosyl pyrophosphate (PRPP)
to hypoxanthine to resynthesize IMP. Adenylosuccinate synthetase, an enzyme of the purine
nucleotide cycle (PNC) can utilize IMP to regenerate AMP, which replenishes the heart's
adenine nucleotides. The availability of O2 during reperfusion allows xanthine oxidase to
convert hypoxanthine to xanthine, a reaction that also synthesizes a burst of ROS. Therefore,
HPRT induction in HIF-1α expressing hearts may also function to minimize ROS production
during ischemia-reperfusion insult.

Figure 6.2: HIF-1α upregulates the mRNA and protein of hypoxanthine phosphoribosyl
transferase (HPRT) in mouse hearts. HPRT mRNA and protein was examined in wildtype (WT)
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mouse hearts and those where the HIF-1α-PPN transgene was suppressed (Non-I), expressed
for 2 days (2D), or expressed for 6 days (6D). a) HPRT gene expression in mouse heart
homogenates was examined using qPCR and normalized to reference gene transferrin. Results
are expressed as the % change in gene expression relative to WT (n=6). b) Representative
Western blot showing HPRT protein expression in mouse heart homogenates (top) and
quantification of HPRT protein levels in mouse heart homogenates (n=4-7). * P<0.05 versus
WT.
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CHAPTER 7
SUMMARY & FUTURE DIRECTIONS
These studies showed that HIF-1α expression allows for strong protection of the
heart during ischemic stress. We observed that ATP preservation during ischemia in
our HIF-1α non-induced hearts (Non-I) was not better compared to wildtype hearts, yet
the Non-I hearts were protected to the same extent as hearts that have been expressing
HIF-1α for 2 and 6 days. These results suggest that the ability to preserve ATP is not
necessarily required to protect the heart from ischemic stress. Evidence showing that
many of the protective mechanisms that lead to ischemic tolerance involve the
protection of the mitochondria is beginning to emerge.

Here we showed that myocytes isolated from HIF-1α Non-I, 2D, and 6D mouse
hearts were able to maintain mitochondrial membrane potential better than myocytes
obtained from wildtype mouse hearts. Previous studies by our group demonstrated that
the HIF-1α signaling axis induces the ability for the mitochondria to use purine
nucleotide cycle derived fumarate as a terminal electron acceptor in place of O2 to
sustain anaerobic mitochondrial respiration. In chapter 3 we showed that AMP
deaminase 2, the entry point to the PNC is upregulated in extracts obtained from 6 day
HIF-1α expressing hearts as compared to wildtype. Here we have obtained evidence
indicating that the protective effects provided by the PNC extends beyond the capability
to maintain mitochondrial membrane potential during ischemia.

Treatment of hearts with hadacidin, inhibitor of the PNC at the step of
adenylosuccinate synthetase followed by ischemia led to a decline in ATP, ATP:ADP,
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and adenylate energy charge. Inhibition of ADSS with hadacidin should reduce the
amount of fumarate available for anaerobic mitochondrial respiration. This will result in
the reversal of the F0F1 ATP synthase in order to maintain the inner membrane potential
of the mitochondria during ischemic stress, which will further deplete ATP. Thus, in
addition to sustaining the mitochondrial membrane potential, the PNC also exerts ATP
sparing effects during ischemia.

A significant finding in these studies is that HIF-1α limited the adenosine that
accumulates in the ischemic heart. While consistent with the shunting of AMP
metabolism towards the PNC rather than the adenosine producing 5'-nucleotidase
pathway, we also find that HIF-1α upregulates adenosine deaminase. Adenosine
deaminase further degrades adenosine to inosine, thereby contributing to the lower
adenosine levels that we have observed in the HIF-1α expressing hearts. Also, we
were surprised to see that IMP accumulation remained lower in HIF-1α expressing
hearts as compared to wildtype mouse hearts during ischemia, even though HIF-1α
upregulates AMP deaminase. Manfredi and Holmes proposed that some mechanism
prevents the accumulation of IMP in the ischemic heart. Taken together, it is likely that
a multitude of factors determine the instantaneous levels of IMP during ischemia. Thus,
we would like to obtain precise quantification of flux through the PNC in the future.

The observation that HIF-1α limits adenosine accumulation in the ischemic heart
contradicts the protective function ascribed to adenosine, particularly from the
perspective of cardioprotection provided by ischemic preconditioning. However, recent
evidence has pointed out that chronic adenosine exposure can lead to toxicity. Future

100

investigations will establish whether HIF-1α can help the ischemic heart avoid
adenosine toxicity.

Our studies have also led to the finding that HIF-1α induces the expression of the
nucleotide salvage enzyme, hypoxanthine phosphoribosyl transferase (HPRT). HPRT
catalyzes a reaction that converts hypoxanthine back to IMP. IMP is then converted
back to AMP via two reaction steps: 1) IMP to S-AMP by adenylosuccinate synthetase;
2) S-AMP to AMP by adenylosuccinate lyase. HPRT may also act in reverse to
metabolize IMP to hypoxanthine. While highly speculative, the increased accumulation
of hypoxanthine during ischemia in HIF-1α expressing versus wildtype hearts maybe
consistent with the faster rate of IMP metabolism by HPRT. This provides a plausible
mechanism that could lead to lower IMP levels in our HIF-1α expressing hearts as
compared to wildtype during ischemia. In addition to its role in adenine nucleotide
salvage, HPRT may also limit the amount of harmful reactive oxygen species (ROS)
generated during reperfusion. Future studies will establish that the induction of HPRT in
HIF-1α expressing hearts allows for better recovery of nucleotides and limits ROSinduced injury during reperfusion.

Taken together, we found that HIF-1α expression in the heart provides strong
protection during ischemic stress. Further, we identified that HIF-1α induces several
metabolic pathways that could contribute to cardioprotection. Future work will aim to
quantify the flux through these metabolic pathways and to further elucidate the role of
these pathways in cardioprotection during ischemia.
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